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ABSTRACT 
 
Anh Tram Nguyen 
Biological functions of DOT1L, the histone H3 lysine 79 methyltransferase 
(Under the direction of Dr. Yi Zhang) 
 
 
The enzymes responsible for epigenetic modifications are key regulators of gene expression, 
ultimately influencing cell fate and function during normal and oncogenic biological 
processes. These modifications can occur on histone proteins of the nucleosome to 
dynamically regulate chromatin structure at active and silenced gene loci. Methylation of 
histone H3 lysine 79 by Dot1 (disruptor of telomeric silencing) was first observed in yeast 
and serves as a marker for active transcription.  Yeast Dot1 is a regulator of telomeric 
silencing, DNA damage repair, and the meiotic pachytene checkpoint.  Additionally, Dot1 
activity is regulated by the PAF complex, Rad6-Bre1 ubiquitination of H2B, and charge-
based interaction with histone H4.  Despite extensive research on Dot1, the role and 
regulation of mammalian homolog DOT1L (Like) is unclear. In this dissertation, I aim to 
understand the biological functions of DOT1L in both normal development and cancer.    
 
In mouse, DOT1L has been linked to embryogenesis and erythropoeisis; however, the 
molecular mechanisms underlying these two processes require further elucidation.  Germ-
line disruption of DOT1L resulted in embryonic lethality with cardiovascular defects. In 
these studies, I demonstrate that DOT1L is required for normal heart function. Cardiac-
specific knockout of DOT1L causes dilated cardiomyopathy (DCM), which can be rescued 
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by ectopic expression of minidystrophin. Mechanistically, DOT1L directly regulates 
transcription of dystrophin, which is critical for maintaining sarcolemma integrity and proper 
heart function. Finally, I provide evidence suggesting that malfunction of DOT1L activity 
may be a contributing factor in human DCM.  
 
Previously, DOT1L has been linked to leukemogenesis caused by chromosomal 
rearrangements of the MLL gene, encoding a histone H3 lysine 4 methyltransferase. 
Specifically, DOT1L enzymatic activity is required for MLL-AF10, MLL-ENL, and MLL-
AF4 in vitro leukemic transformation. In these studies, I sought to expand the repertoire of 
MLL-fusion oncoproteins that utilize DOT1L by investigating MLL-AF9 leukemogenesis. 
Through in vitro and in vivo assays, I demonstrate that initial transformation by MLL-AF9 
and maintenance of leukemic stem cell identity require DOT1L activity. These data support a 
universal mechanism involving mis-targeting of DOT1L and H3K79 hypermethylation for 
the up-regulation of leukemia-associated genes. Thus, DOT1L serves as a promising 
candidate for targeted therapeutics to treat MLL-related leukemias. 
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Chapter 1 
INTRODUCTION
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Epigenetic contribution to cellular diversity 
Every cell within an organism is derived from a single totipotent fertilized egg. Although 
each cell contains the same exact genetic information, very different cellular identities arise 
during development to ultimately form all the tissues and organs of the organism. How this 
remarkable phenomenon occurs in the developing embryo was commented on by Conrad 
Waddingtion in his book, An Introduction to Modern Genetics.  
It is, surely, obvious that the fertilized egg contains constituents which have 
definite properties which allow only a certain limited number of reactions to 
occur; in so far as this is true, one may say that development proceeds on a 
basis of the “preformed” qualities of the fertilized egg. But equally it is clear 
that the interaction of these constituents gives rise to new types of tissue and 
organ which were not present originally, and in so far development must be 
considered as “epigenetic”. (Waddington 1939) 
  
As such, the term “epigenetics” is credited to Conrad Waddington who later defined it as “the 
branch of biology which studies the causal interactions between genes and their products, 
which bring the phenotype into being” (Waddington 1942). Epigenetics has now evolved to 
refer to the heritable changes in gene expression that occur without changes in the underlying 
DNA sequence. Today we understand that the dynamic nature of chromatin is a major 
contributor to the establishment, maintenance, and variances in differential gene expression 
within any given cell type.  
 
Two meters of eukaryotic DNA must be tightly condensed into chromatin to fit within the 
cell nucleus.  Nucleosomes, containing 147 bp of DNA wrapped around a histone octamer 
(H3/H4 heterotetramer and two H2A/H2B dimers) serve as the basic building block for 
compaction into chromatin (Van Holde, Allen et al. 1980; Luger, Mader et al. 1997; 
Kornberg and Lorch 1999; Zhang and Dent 2005).  In this highly compressed state, all DNA-
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dependent processes, including replication and transcription, are hindered.  
 
The four core histones, H3, H4, H2A, and H2B, are comprised of a globular domain and 
unstructured NH3-, COOH- tails that protrude from the nucleosome center (Luger, Mader et 
al. 1997; Martin and Zhang 2005; Zhang and Dent 2005).  These tails may influence histone-
DNA interactions as well as histone-histone interactions to dynamically control the 
accessibility state of DNA for transcription.  Histones undergo post-translational 
modifications such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation, 
and ribosylation.  These modifications influence chromatin structure and function directly or 
indirectly through the recruitment of effector proteins at heterochromatic (silenced genes) 
and euchromatic (active genes) regions (Strahl and Allis 2000; Martin and Zhang 2005; 
Kouzarides 2007). 
 
The epigenetic factors responsible for these histone modifications are key regulators of gene 
expression, cell lineage commitment, and oncogenesis.  In particular, methylation of histones 
has been shown to be critical in development (Cavalli 2006; Minard, Jain et al. 2009).  
Altered methylation by disruption of histone methyltransferase (HMTase) activity affects the 
expression level of both tumor suppressors and oncogenes, and has been implicated in 
hematologic, breast, prostate, and lung cancers (Feinberg, Oshimura et al. 2002; Handel, 
Ebers et al. 2009).  Specifically, H3 methylation is important for X-inactivation, cell fate, 
terminal differentiation, and the spatio-temporal patterning of Hox genes during 
embryogenesis (Cavalli 2006; Minard, Jain et al. 2009).   
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Histone lysine methylation 
In mammals, lysine methylation exists in the mono-, di-, and tri- states, occurring on histone 
H3 at residues K4, K9, K27, K36, and K79 and on histone H4 at residue K20 (Zhang and 
Reinberg 2001; Martin and Zhang 2005).  These marks serve as a platform for the 
recruitment of effector proteins to regulate transcription. For example, H3K4me recruits 
activating proteins such as remodeling factors Chd1 and NURF and histone acetyltransferase 
complexes SAGA and NuA3 as well as the repressive deacetylase complex Sin3-Ndac1 
(Berger 2007).  Additionally, H3K36me is thought to recruit a histone deacetylase complex 
(Carrozza, Li et al. 2005; Joshi and Struhl 2005; Keogh, Kurdistani et al. 2005), while 
H3K9me recruits HP1 for the formation of pericentromeric heterochromatin (Bannister, 
Zegerman et al. 2001; Lachner, O'Carroll et al. 2001; Nakayama, Rice et al. 2001).  The 
multitude of effector or “reader” proteins and their associated binding modules has been 
extensively reviewed by Taverna et al. (Taverna, Li et al. 2007).  
 
Histone methylation results from the transfer of a methyl group from S-adenosylmethionine 
(SAM) to nitrogen atoms of lysine and arginine residues.  Two classes of lysine 
methyltransferases exist. The first class of proteins contain an evolutionarily conserved SET 
(Su(var)3-9, Enhancer of Zeste (E(Z)), Trithorax (trx)) domain, first identified in D. 
melanogastor (Zhang and Reinberg 2001; Zhang and Dent 2005).  The second class does not 
possess a SET domain, but rather, a catalytic methylase fold resembling that of class I 
methyltransferases (Ng, Feng et al. 2002; Min, Feng et al. 2003; Schubert, Blumenthal et al. 
2003). Methylation at H3K9, H3K27, and H4K20 demarcate transcriptionally inactive genes, 
while H3K4, H3K36, and H3K79 methylation are indicative of actively transcribed genes 
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(Kouzarides 2002; Peterson and Laniel 2004; Martin and Zhang 2005).   
 
Dot1-mediated H3K79 methylation marks active transcription 
Dot1 (disruptor of telomeric silencing) is the only member of the second class of lysine 
methyltransferases. The DOT1 gene contains four sequence motifs – I, post I, II, and III – 
that form an open α/β structure composed of a seven-stranded β-sheet, which is characteristic 
of the catalytic methylase fold found in arginine methylases (Cheng and Roberts 2001; 
Dlakic 2001; Min, Feng et al. 2003; Sawada, Yang et al. 2004). Despite its structure, yeast 
Dot1 and its mammalian homolog DOT1L, are histone H3 lysine 79 (H3K79) 
methyltransferases, whose substrate site is located within the globular domain of histone H3 
instead of its N-terminal tail (Feng, Wang et al. 2002; Lacoste, Utley et al. 2002; van 
Leeuwen, Gafken et al. 2002; Zhang, Hayashizaki et al. 2004). 
 
Dot1 was originally identified in S. cerevisiae as a regulator of telomeric silencing (Singer, 
Kahana et al. 1998).  Conflicting data supports a requirement for both the presence and 
absence of H3K79 methylation to mediate association of SIR (silent information regulator) 
proteins, heterochromatic formation, and telomeric silencing in a mechanism reminiscent of 
position-effect-variegation observed in D. melanogastor.  Surprisingly, over-expression and 
deletion of Dot1 and mutation of H3K79 results in a loss of telomeric silencing (Singer, 
Kahana et al. 1998; Ng, Feng et al. 2002; Ng, Ciccone et al. 2003).  In all three cases, the 
level of SIR proteins bound at telomeres is reduced thus limiting their ability to silence 
genes.  Since ~90% of the yeast genome is methylated at H3K79 and the remaining ~10% 
account for transcriptionally silenced genes, it is thought that H3K79 methylation by Dot1 
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affects the distribution of SIR proteins and serves as a euchromatic mark (Laurenson and 
Rine 1992; van Leeuwen, Gafken et al. 2002).  
 
Data from several genome-wide profile analyses also support a role for H3K79 methylation 
in active transcription. Using chromatin immunoprecipitation (ChIP) coupled with gene 
expression microarray analysis, Schübeler et al. mapped the chromatin modification status of 
over 5000 Drosophila genes. They discovered that the presence of histone acetylation, 
H3K4me2, H3K4me3, and H3K79me2 positively correlate with active gene transcription 
(Schubeler, MacAlpine et al. 2004). Another study used ChIP-Chip with mouse 3T3 cells to 
show that H3K79 methylation marks are localized within the body of transcribed genes and 
that the amount of enrichment correlated with expression level (Steger, Lefterova et al. 
2008). Furthermore, Zhao and colleagues used human CD4+ T cells to show that all levels of 
H3K79 methylation coincide with active transcription (Wang, Zang et al. 2008). 
Collectively, analyses of yeast, fly, mouse, and human genomes all reveal that H3K79 
methylation is marker of euchromatin. 
 
Trans-histone crosstalk regulates Dot1 enzymatic activity 
During characterization of DOT1L enzymatic activity, it was observed that DOT1L 
preferentially methylates H3K79 in the context of nucleosomes rather than core histones or 
recombinant H3 (Feng, Wang et al. 2002). Based on the nucleosome structure, K79 lies 
within loop 1 that connects the first and second α-helices of the histone H3 globular domain 
and is in close proximity to histone H2B lysine 123 (H2B-K123) (Luger, Mader et al. 1997). 
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The unique position of H3K79 suggested that a trans-histone crosstalk may play a role in 
regulating DOT1L enzymatic activity. 
 
In yeast, histone H2B is monoubiquitinated at lysine 123 (H2B-K123ub). This modification 
is catalyzed by the ubiquitin-conjugating enzyme Rad6 and its E3 ubiquitin ligase Bre1 
(Robzyk, Recht et al. 2000; Wood, Krogan et al. 2003). Shortly after the characterization of 
Dot1 enzymatic activity, it was discovered that Rad6-mediated H2B-K123 ubiquitination is 
required for H3K79 methylation (Briggs, Xiao et al. 2002; Ng, Xu et al. 2002). This trans-
histone regulation did not appear to play a general role in histone methylation as H3K36 
methylation is unaffected by Rad6 deletion (Briggs, Xiao et al. 2002; Ng, Xu et al. 2002). 
The role of H2B ubiquitination in trans-histone crosstalk is evolutionarily conserved as 
human Bre1 was found to regulate ubiquitination of H2B-K120, corresponding to K123 in 
yeast, and, subsequently, methylation of and H3K79 (Ng, Robert et al. 2003). The PAF 
complex, composed of the proteins Rtf1, Paf1, Cdc73, Leo1, and Ctr9, associates with the 
elongating form of RNA Pol II (Costa and Arndt 2000; Mueller and Jaehning 2002; 
Pokholok, Hannett et al. 2002; Squazzo, Costa et al. 2002) and also regulates Dot1-mediated 
H3K79 methylation (Krogan, Dover et al. 2003). Mechanistically, Rtf1 and Paf1 are required 
for Rad6-Bre1 ubiquitination of H2B-K123, which, in turn, modulates H3K79 methylation 
(Krogan, Dover et al. 2003; Ng, Dole et al. 2003; Wood, Schneider et al. 2003).  
 
In addition to H2B-K123 ubiquitination, interaction with histone H4 also regulates Dot1 
enzymatic activity. Mutational analysis identified a basic patch within histone H4 tail 
(R17H18R19) that is required for Dot1 interaction with histone H4 and for H3K79 methylation 
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but not H3K4 or H3K36 methylation (Fingerman, Li et al. 2007). Interestingly, post-
translational modifications of histone H4, including acetylation and phosphorylation, have no 
effect on H3K79 methylation (Altaf, Utley et al. 2007).  
 
Although Dot1 retains the ability to bind nucleosomes in the absence of histone H4 tail or its 
basic patch, loss of these two regions still affect H3K79 methylation (Altaf, Utley et al. 2007; 
Fingerman, Li et al. 2007), suggesting allosteric regulation of Dot1 enzymatic activity 
through R17H18R19 binding. Since the positive charge of R17H18R19 was most critical in 
regulating H3K79 methylation, it was reasoned that a negatively charged, acidic patch may 
exist in Dot1. Correspondingly, an acidic patch, EDVDE, within an exposed loop structure of 
the C-terminus of yeast Dot1 (aa 557-561) was shown to be required for Dot1 interaction 
with histone H4 tail and for di- and tri-methylation of H3K79 (Fingerman, Li et al. 2007). 
Collectively, these data exemplify intra-nucleosome cross-talk to regulate HMTase activity 
for tight control of gene expression. 
 
Dot1 and the cell cycle response to DNA damage 
Prior to cell division, the entire genome of a proliferating cell must be replicated in a highly 
efficient and accurate manner to preserve genetic integrity and genome stability. Therefore, 
progression through the cell cycle is tightly regulated by a number of checkpoints that 
become activated in response to DNA damage induced by both intrinsic and extrinsic factors. 
Several studies have linked Dot1 and its associated H3K79 methylation marks to DNA 
damage checkpoint function and repair in response to numerous extrinsic-induced injuries. 
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Human 53BP1 protein contains a tandem tudor domain that binds to methylated H3K79 and 
is recruited to DNA double strand breaks (DSBs). Strikingly, mutation of the tudor domain 
and Lys 79 of H3 or suppression of DOT1L all inhibit recruitment of 53BP1 to DSBs. Since 
H3K79 methylation levels do not accumulate upon DNA damage, it is believed that DSBs 
induce changes in chromatin structure to expose methylated H3K79, which are then 
recognized by 53BP1 (Huyen, Zgheib et al. 2004). The interaction of 53BP1 to H3K79me is 
evolutionarily conserved as Rad9, the yeast ortholog of 53BP1, also binds to H3K79me via 
its Tudor domain. In addition, loss of Dot1-mediated H3K79 methylation disrupts the 
activation and recruitment of Rad9 and phosphorylation of Rad53 upon ionizing radiation 
(IR) damage (Wysocki, Javaheri et al. 2005). Budding yeast cells treated with IR at G1 
typically undergo a G1 checkpoint delay. Interestingly, Dot1 mutants are defective in G1 and 
intra-S phase checkpoints and progress through the cell cycle at a normal rate even after IR 
induced DNA damage (Wysocki, Javaheri et al. 2005). In addition, mutations that affect 
Dot1 methyltransferase activity such as disruption of H2B-K123 ubiquitination or mutation 
of H3K79 display the same checkpoint delay defects in response to multiple genotoxic 
stresses (Giannattasio, Lazzaro et al. 2005; Game, Williamson et al. 2006; Chernikova, Dorth 
et al. 2010).  
 
In response to IR damage, the DOT1/Rad6/Bre1 pathway mediates G1 homologous 
recombination repair (Game, Williamson et al. 2006). Although dot1 deletion mutants do not 
display a G2 arrest phenotype (Game, Williamson et al. 2006), Dot1 is required for Rad9 
recruitment to repair foci at G2 upon IR-induced damage (Toh, O'Shaughnessy et al. 2006). 
It is proposed that Dot1-mediated H3K79 methylation plays two distinct roles during Rad9 
 10 
 
DNA damage response, the first being G1/S checkpoint activation and the second being late 
G2 DNA repair (Grenon, Costelloe et al. 2007).  
 
Repair of DSBs can occur via homologous recombination (HR) or nonhomologous end 
joining (NHEJ). HR with the sister chromatid (SCR) in mitosis ensures faithful transmission 
of the genetic material. A number of proteins, including cohesin, are required to maintain 
chromosome structure and for efficient SCR. Interestingly, not only is Dot1 required for the 
proper recruitment of Rad9 to sites of DSBs, it also promotes recruitment of cohesin and is 
necessary for efficient SCR (Conde, Refolio et al. 2009). Resection of DSBs is an important 
step in DNA damage repair, producing 3’ single-stranded DNA (ssDNA) tail intermediates. 
It was demonstrated that H3K79 methylation and Rad9 recruitment play an integral role in 
regulating resection to limit the amount of ssDNA that is produced (Lazzaro, Sapountzi et al. 
2008).  
 
Ultraviolet radiation (UV) causes formation of cis-syn cyclopyrimidine and 6-4 photoproduct 
dimers, which can be repaired by nucleotide excision repair (NER), recombination repair, 
and post-replication repair (PRR). Dot1 and its associated H3K79 methylation are required to 
elicit an appropriate response to UV damage (Giannattasio, Lazzaro et al. 2005) with loss of 
methylation affecting all three repair pathways, resulting in hypersensitivity (Bostelman, 
Keller et al. 2007; Lazzaro, Sapountzi et al. 2008). When DNA damage cannot be repaired, 
cell cycle progression and cell survival may be achieved by the translesion synthesis pathway 
(TLS) that utilizes error-prone polymerases to bypass DNA lesions. Evidence indicate that 
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Dot1 negatively regulates TLS, thereby maintaining genome integrity upon DNA damage 
(Conde and San-Segundo 2008; Conde, Ontoso et al. 2010; Levesque, Leung et al. 2010). 
 
Diploid parental cells undergo meiotic cell division to generate haploid gametes. Proper 
segregation of chromosomes during meiosis is ensured by the pachytene checkpoint, which 
monitors completion of chromosome synapsis and recombination to prevent premature 
nuclear division. In the event of defective meiotic recombination, the pachytene checkpoint 
induces arrest at mid-meiotic prophase. In yeast, arrest at pachytene can be observed in dmc1 
and zip1 mutants, which are required for proper synapsis formation and repair of DSBs. In a 
genetic screen for pachytene checkpoint components, it was observed that dmc1 and zip1 
mutants failed to arrest in the absence of Dot1. The failure to arrest is in part due to mis-
localization of the nucleolar proteins Pch2 and Sir2, both required for pachytene checkpoint 
function (San-Segundo and Roeder 2000). 
 
Collectively, an overwhelming amount of data supports a vital role for DOT1 in regulating 
cell cycle progression in yeast upon DNA damage. Surprisingly, very little work has been 
performed to determine if Dot1’s role in checkpoint function is evolutionarily conserved. 
With respect to mouse DOT1L, reports show that the depletion of DOT1L elicits cell cycle 
arrests at both G1 and G2 in the absence of extrinsic-induced DNA damage; however, the 
molecular mechanisms governing these phenotypes have not been addressed (Jones, Su et al. 
2008; Barry, Krueger et al. 2009; Feng, Yang et al. 2010) .  
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DOT1L regulatory role in cardiovascular development 
The majority of research dedicated to understanding the function of Dot1-mediated H3K79 
methylation were performed in yeast. When I first began my Ph.D. training in Dr. Zhang’s 
lab, the only biological function known about mammalian DOT1L was its mis-targeting in 
leukemia. DOT1L and its associated methylation marks are evolutionarily conserved from 
yeast to humans, suggesting that it may have critical biological roles in mammals. Therefore, 
I sought to elucidate DOT1L biological functions using the mouse as a model system with a 
focus on the cardiovascular system.  
 
The first indication of a DOT1L regulatory function in cardiac development arose from ex 
vivo studies investigating epigenetics in cardiac development.  Mouse ES cells exposed to 
laminar shear stress undergo myocardiogenesis.  During this process there is a correlation 
between increased H3K79 methylation and induced expression of cardiovascular marker 
genes, such as vascular endothelial growth factor (VEGF) receptor 2, smooth muscle actin 
(SM-actin), smooth muscle protein 22-alpha (SM22-α), platelet-endothelial cell adhesion 
molecule-1 (PECAM-1), myocyte enhancer factor-2C (MEF2C), and α-sarcomeric actin (Illi, 
Scopece et al. 2005).   In addition, analysis of differentiated/lineage specific cells revealed 
that the transcription activator SRF (serum response factor) binds to a distinct histone 
modification signature at smooth muscle specific promoters (H3K4me2, H3K79me2, 
H3K9ac, H4ac) (McDonald, Wamhoff et al. 2006).   
 
In collaboration with the Epigenetics Program at Novartis, we generated a DOT1L 
conditional knockout mouse. Germ-line deletion of DOT1L resulted in embryonic lethality 
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after the onset of organogenesis at E9.5-E10.5.   Knockout embryos displayed defects in the 
cardiovascular system such as heart enlargement, decreased vasculature, and reduced red 
blood cells (Jones, Su et al. 2008). Collectively, these phenotypes suggested a DOT1L 
regulatory function in cardiovascular and hematopoiesis development. Subsequently, Fields 
and colleagues demonstrated that primitive erythropoiesis requires DOT1L. In the absence of 
DOT1L, erythroid progenitor cells undergo a G1 cell cycle arrest and fail to differentiate 
(Feng, Yang et al. 2010).   
 
The heart enlargement phenotype observed in knockout embryos may be a primary 
abnormality due to DOT1L loss of function or a secondary defect in response to insufficient 
blood supply from a reduced vasculature network or defective erythropoiesis.  To elucidate 
the role of DOT1L in cardiac development and/or function, we generated a cardiac-specific 
knockout mouse model, which is the focus of my first project. A further understanding of 
DOT1L’s regulatory role in cardiac function may provide insight into the genetic causes of 
congenital heart diseases and lead to the development of novel gene therapies. 
 
Mis-targeting of DOT1L in MLL-related leukemias 
Chromosomal translocation of the MLL (mixed lineage leukemia) gene results in the 
expression of oncogenic fusion proteins and is a common cause of acute leukemia (Ayton 
and Cleary 2001; Hess 2004). MLL rearrangements account for 7-10% of acute lymphoid 
leukemias (ALL) and 5-6% of acute myeloid leukemias (AML). In addition, ~10% of these 
MLL-related leukemias are caused by chemotherapy (Daser and Rabbitts 2004). Importantly, 
MLL rearrangements account for ~80% of ALL and ~60% of AML infant leukemias (Ayton 
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and Cleary 2001; Hess 2004; Krivtsov and Armstrong 2007). Due to the high incidence of 
MLL-mediated acute leukemias, a better understanding of the molecular mechanisms utilized 
by MLL-fusion proteins is vital for the development of effective treatments. 
 
MLL, an H3K4 methyltransferase, aids in maintaining the “on” state of Hox gene expression 
during embryonic development and hematopoiesis (Hsieh, Cheng et al. 2003; Guenther, 
Jenner et al. 2005). In acute myeloid leukemia, genes of the Hoxa cluster are frequently up-
regulated and have been shown to be required for leukemogenesis (Argiropoulos and 
Humphries 2007; Guenther, Lawton et al. 2008). While the catalytic domain of MLL is 
removed upon translocation, its N-terminus, containing two DNA-binding domains (AT-
hooks and DNMT homology region) and subnuclear localization motifs is retained in fusion 
proteins.  Thus, MLL-fusion proteins are likely directed to genes targeted by MLL.  
Meanwhile, aberrant regulation of gene expression for leukemogenesis is mediated by 
activity of wild type MLL expressed from the non-mutant allele and by the fusion partner 
(Li, Liu et al. 2005; Krivtsov and Armstrong 2007).   
 
Among the over 50 MLL fusion partners, AF4, AF9, AF10, ENL, and ELL account for 2/3 
of all MLL-associated leukemias.   With the exception of ELL, the other four proteins have 
been reported to associate with each other through direct and indirect protein-protein 
interactions, suggesting that a common mechanism may be exploited during leukemia 
development (Slany 2005; Krivtsov and Armstrong 2007). Interestingly, DOT1L has also 
been shown to associate with a number of MLL-fusion partners and participates in the 
activation of a leukemic transcriptional program (Okada, Feng et al. 2005; Zhang, Xia et al. 
 15 
 
2006; Bitoun, Oliver et al. 2007; Mueller, Bach et al. 2007; Krivtsov, Feng et al. 2008; 
Mueller, Garcia-Cuellar et al. 2009). 
 
For example, the Zhang lab previously demonstrated that DOT1L specifically associates with 
the OM-LZ region of AF10 and is required for leukemic transformation by MLL-AF10.  
Importantly, it was shown that mis-targeting of DOT1L to the Hoxa9 gene and subsequent 
activation of Hoxa9 by H3K79 hypermethylation contributes to the transformation capability 
of MLL-AF10 (Okada, Feng et al. 2005).   AF17, another fusion partner of MLL, has an 
OM-LZ domain similar to that of AF10, making it a potential DOT1L interacting protein 
(Prasad, Leshkowitz et al. 1994).  Through mutating ENL, Mueller et al. were able to 
demonstrate that DOT1L interaction is required for MLL-ENL transformation and increased  
expression of Hoxa7 and Hoxa9 (Mueller, Bach et al. 2007).  Furthermore, knockdown of 
DOT1L in MLL-AF4 transformed cells impaired proliferation and caused down-regulation of 
Hoxa genes (Krivtsov, Feng et al. 2008).  
 
Collectively, these data support a universal mechanism by which DOT1L is mis-targeted to 
gene loci for aberrant H3K79 methylation and transcriptional activation to promote MLL-
mediated leukemogenesis. To further support this common pathway, my second project 
focuses on the role of DOT1L in MLL-AF9 leukemia development. I will utilize our DOT1L 
knockout mouse model in combination with bone marrow transplantation to investigate 
whether DOT1L is essential for in vivo acute leukemia development and progression, which 
has not been demonstrated before. The findings from this project may lead to the 
development of novel target-based drugs for the treatment of MLL-related leukemias. 
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Abstract 
Histone methylation plays an important role in regulating gene expression. One such 
methylation occurs at lysine 79 of histone H3 (H3K79) and is catalyzed by the yeast Dot1 
(disruptor of telomeric silencing) and its mammalian homolog DOT1L. Previous studies have 
demonstrated that germ line disruption of Dot1L in mouse resulted in embryonic lethality. 
Here we report that cardiac-specific knockout of Dot1L results in increased mortality rate 
with chamber dilation, increased cardiomyocyte cell death, systolic dysfunction, and 
conduction abnormalities.  These phenotypes mimic those exhibited in patients with dilated 
cardiomyopathy (DCM).  Mechanistic studies reveal that DOT1L performs its function in 
cardiomyocytes through regulating Dystrophin (Dmd) transcription and, consequently, 
stability of the Dystrophin-glycoprotein complex important for cardiomyocyte viability. 
Importantly, expression of a mini-Dmd can largely rescue the DCM phenotypes indicating 
that Dmd is a major target mediating DOT1L function in cardiomyocyte. Interestingly, 
analysis of available gene expression data sets indicates that DOT1L is down-regulated in 
idiopathic DCM patient samples compared to normal controls. Therefore, our study not only 
establishes a critical role for DOT1L-mediated H3K79 methylation in cardiomyocyte 
function, but also reveals the mechanism underlying the role of DOT1L in DCM. In addition, 
our study may open new avenues for the diagnosis and treatment of human heart disease. 
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Introduction 
Chromatin is subject to reversible post-translational modifications that may directly alter 
chromatin structure and function or indirectly through the recruitment of effector proteins at 
heterochromatic (silenced) and euchromatic (active) DNA. Histone methylation plays an 
important role in regulating transcription at target loci and is important for X-inactivation, 
cell fate maintenance, and terminal differentiation (Peterson and Laniel 2004; Martin and 
Zhang 2005; Kouzarides 2007). One particular histone methylation event occurs at Lysine 79 
within the globular domain of histone H3 (H3K79) and is catalyzed by yeast Dot1 (disruptor 
of telomeric silencing) and its mammalian homolog DOT1L (Feng et al. 2002; Lacoste et al. 
2002; Ng et al. 2002a; van Leeuwen et al. 2002). Although Dot1 was originally identified as 
a regulator of telomeric silencing (Singer et al. 1998), more recent studies suggest that Dot1-
mediated H3K79 methylation is linked to euchromatic gene transcription (Schubeler et al. 
2004; Barski et al. 2007; Steger et al. 2008).  
 
In yeast, Dot1 activity is positively regulated during transcription elongation through Rad6-
Bre1 mono-ubiquitination of H2B (Ng et al. 2002b; Krogan et al. 2003; Wood et al. 2003). 
Additionally, Dot1 has been linked to the meiotic pachytene checkpoint control (San-
Segundo and Roeder 2000) and DNA damage repair (Giannattasio et al. 2005; Wysocki et al. 
2005; Conde et al. 2009). However, the biological function of mammalian DOT1L, 
particularly in the context of the animal, is less characterized. A recent study indicates that 
DOT1L exists in a large protein complex and regulates the expression of Wingless target 
genes (Mohan et al. 2010). We and others have previously demonstrated that mis-targeting of 
DOT1L and subsequent H3K79 hypermethylation plays an important role in leukemic 
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transformation (Okada et al. 2005; Okada et al. 2006; Mueller et al. 2007; Krivtsov et al. 
2008). Most recently, DOT1L has been shown to regulate the erythroid and myeloid lineage 
switch during differentiation (Feng et al. 2010). In addition, loss of function studies revealed 
a critical role of DOT1L during mouse embryogenesis as germ-line Dot1l knockout (KO) 
causes lethality at embryonic day E10.5 with growth impairment, yolk sac angiogenesis 
defects, and cardiac dilation (Jones et al. 2008).   
 
Congestive heart failure (CHF) is a common manifestation of cardiomyopathy, a disease 
caused by malfunction of the heart muscle (Seidman and Seidman 2001; Liew and Dzau 
2004).  Dilated cardiomyopathy (DCM) is characterized by dilation of the left or both 
ventricles and reduced contractile function (systolic dysfunction), and is the most prevalent 
form of cardiomyopathy (Seidman and Seidman 2001; Liew and Dzau 2004). Recent studies 
suggest that, in addition to genetic alterations, epigenetic factors also contribute to DCM. For 
example, several studies have linked histone acetylation to cardiac hypertrophy and DCM 
(Zhang et al. 2002; Kook et al. 2003; Montgomery et al. 2007; Ha et al. 2010; Hang et al. 
2010). However, whether histone methylation contributes to DCM is not clear, although 
dysregulation of histone methylation has been linked to a number of human diseases 
(Feinberg et al. 2002; Handel et al. 2009).  
 
To further characterize the function of DOT1L in the mouse heart, we generated a 
cardiomyocyte-specific knockout mouse model using the α-MHC-Cre line and demonstrate 
that DOT1L plays an important role in heart function. We provide evidence suggesting that 
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dysregulation of Dystrophin in cardiomyocytes is largely responsible for the phenotypes 
exhibited in the Dot1L cardiac conditional knockout mice. 
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Results 
Dot1L deficiency in cardiomyocytes does not cause embryonic lethality 
Previous studies demonstrate that germ-line Dot1l knockout (KO) causes lethality at 
embryonic day E10.5 with diverse impairments that include growth retardation, yolk sac 
angiogenesis defects, and cardiac dilation (Jones et al. 2008).  To understand the molecular 
mechanism underlying the embryonic phenotypes, we take advantage that the Dot1L 
conditional allele contains a promoterless β-geo cassette (Jones et al. 2008) and analyzed 
Dot1L expression by X-gal staining. This study revealed that the heart is one of the highest 
Dot1L-expressing organs (Figure S2-1A). RT-qPCR analysis also indicates that cardiac 
expression of Dot1L peaks after birth (Figure S2-1B). This Dot1L expression pattern in 
combination with the timing of lethality suggests that heart defects might contribute to the 
embryonic lethality phenotype.  
 
To explore a role for DOT1L in the heart, we generated a cardiac-specific conditional 
knockout mouse model by first crossing DOT1L2lox/+ and DOT1L1lox/+ with the (α-myosin 
heavy chain) α-MHC-Cre line (Abel et al. 1999) (Figure S2-2A). Cardiac conditional 
knockout (referred to as CKO for the remainder of the manuscript), DOT1L2lox/1lox;α-MHC-
Cre, mice were then obtained by crossing DOT1L2lox/+;α-MHC-Cre mice with 
DOT1L1lox/+;α-MHC-Cre mice.  Cre-mediated deletion results in removal of 108 amino acids 
in the catalytic domain of DOT1L, rendering an enzymatically inactive DOT1L (Figure S2-
2B). CKO mice were born at Mendelian ratio (Figure S2-2C) and recombination efficiency 
was verified by RT-qPCR using hearts derived from new-born, postnatal day 1 (P1) mice 
(Figure S2-2D). Consistent with loss function of DOT1L in the CKO hearts, Western blot 
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analysis and immunostaining using an antibody that recognizes both di- and tri-methylation 
of H3K79 (H3K79me2/3) demonstrate loss of H3K79me2/3 in the CKO hearts (Figure S2-
2E, F). These results suggest that loss function of DOT1L in cardiomyocytes alone is not 
sufficient to cause embryonic lethality.  
 
DOT1L deficiency in cardiomyocytes causes heart dilation and postnatal lethality  
Although CKO mice are born in Mendelian ratio, sudden death was observed in 50% of the 
CKO mice within two weeks after birth, and the remaining 50% CKO mice die by six 
months of age (Figure 2-1A), indicating DOT1L has an important function in postnatal and 
adult cardiomyocytes. Analysis of the CKO mice revealed severely enlarged hearts (Figure 
2-1B) and dilation of both chambers (Figure 2-1C). Consistently, heart to body weight ratios 
were also increased in CKO mice compared with that of their littermate controls (Figure 2-
1D).  The increased heart to body weight ratio is mainly caused by increased heart weight 
(Figure 2-1E) as the body weight is not significantly altered between WT and CKO mice 
(Figure S2-3A).   
 
To determine whether concentric hypertrophy contributes to the increase in CKO heart mass, 
tissue sections were stained with Laminin antibody followed by measuring cardiomyocyte 
circumference. Quantification using ImageJ software indicates that the average cell 
circumference is not altered in CKO mice (Figure S2-3B, C), suggesting that the increase in 
CKO heart mass is in part due to eccentric hypertrophy. These data collectively indicate that 
loss of DOT1L function, particularly its H3K79 methyltransferase activity, in 
 30 
 
cardiomyocytes results in congestive heart failure (CHF) that is likely due to dilated 
cardiomyopathy (DCM).  
 
CKO hearts exhibit similar cardiac remodeling observed in DCM patients  
In addition to chamber dilation, gross changes in heart morphology, such as deviation from 
an elliptical shape to a more spherical one and increased heart mass, was also observed 
(Figure 2-1C, E) indicating loss function of DOT1L in cardiomyocytes caused cardiac 
remodeling. Since DCM is often accompanied with pathologic remodeling (Cohn et al. 
2000), we analyzed the histopathology of CKO hearts at P10. TUNEL staining revealed a 
dramatic increase in apoptotic cell death in CKO hearts compared to the WT control (Figure 
2-2A). In addition, transmission electron microscopic (TEM) analysis revealed a significant 
increase of vacuoles in CKO myocytes (Figure 2-2B, ii, arrows), suggesting an increase in 
autophagic cell death, consistent with previous studies linking autophagy to DCM (Knaapen 
et al. 2001). In addition, TEM also revealed interstitial fibroblast cells in CKO heart tissue 
(Figure 2-2B, compare i. and iii.) indicating reactive fibrosis, a common feature of cardiac 
remodeling found in DCM (de Leeuw et al. 2001; Luk et al. 2009), took place in CKO hearts. 
Additionally, immunostaining with anti-HSPG2 (also known as Perlecan) shows increased 
interstitial HSPG2 staining (Figure 2-2C, arrowheads) as well as increased HSPG2 and 
myofibroblasts lining the inner left ventricular chamber (Figure 2-2C, yellow outlined) in 
CKO hearts supporting the presence of reactive fibrosis, which is further confirmed by 
Masson’s Trichrome staining (Figure 2-2D, blue staining).  
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Previous studies have established that reactivation of a fetal gene expression program and 
increase in cellular proliferation is concomitant with the degeneration of cardiomyocytes in 
DCM (Kajstura et al. 1998; Cohn et al. 2000; Houweling et al. 2005). Consistent with the 
notion that DOT1L deficiency resulted in DCM, RT-qPCR demonstrated that expression of 
the fetal genes Myh7, Acta1, Nppa, and Nppb are up-regulated in CKO hearts (Figure 2-2E). 
In contrast, adult gene Myh6 is down-regulated. Mouse cardiomyocytes retain a small 
capacity to proliferate after birth (Ahuja et al. 2007; Banerjee et al. 2007). To determine 
whether DOT1L deficiency results in an increased cell proliferation, as exhibited in DCM, 
heart tissue sections were immunostained for Ki-67 at P1 and P5.  Results shown in Figure 2-
2F demonstrate that the percentage of proliferating cells (ratio of Ki-67 positive nuclei to 
total nuclei, multiplied by 100) is significantly increased in the CKO hearts compared to the 
control, which may contribute to the observed increase in the CKO heart mass. We note that 
this increased cell proliferation in the DOT1L-deficient heart is in contrast to previous 
studies showing a requirement for DOT1L in ES cell cycle progression (Jones et al. 2008; 
Barry et al. 2009), suggesting cell type specificity. Taken together, the above data support 
that CKO hearts exhibit multiple phenotypes similar to those observed in DCM. 
 
CKO hearts exhibit similar functional defects observed in DCM patients  
To gain further support that DOT1L deficiency in cardiomyocytes results in DCM, we asked 
whether the morphological changes and cardiac remodeling observed in CKO hearts affect 
their function. To this end, we performed echocardiography (ECHO) analysis at different 
mouse age groups. Conscious ECHOs performed on P10 pups during the first stage of 
lethality (n=5 per genotype) demonstrate that CKO mice have increased left ventricular 
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internal dimensions and volume. Analysis of cardiac output by measuring ejection fraction 
(EF) and fractional shortening (FS) revealed that both EF and FS is reduced by almost half in 
CKO mice when compared with that of WT mice (Table 2-1). These results are indicative of 
left ventricular systolic dysfunction and are consistent with clinical DCM outcome 
(Karkkainen and Peuhkurinen 2007; Luk et al. 2009). Similar results were obtained at 2 and 
5 months of age (Table 2-1). Interestingly, the smaller difference between WT and CKO 
mice at 2 months may reflect a compensation that allowed these mice to bypass the first stage 
of lethality. 
 
Cardiac conduction abnormalities are frequently observed in DCM heart failure patients with 
left ventricular systolic dysfunction (Olson 2004).  During heart contraction, an electrical 
impulse transmits from atria (P-wave) to ventricles (QRS-wave) at the atrioventricular node 
(AVN). The time delay for electrical propagation can be directly measured by 
electrocardiography (EKG) (Hatcher and Basson 2009). To determine whether the 
conduction system is perturbed in CKO mice, EKG was performed at 5 months of age (n=8 
per genotype). All CKO mice displayed minimally a first degree heart block at the AVN, 
with an 80% penetration of either non-sustained ventricular tachycardia (n=1/8) (Figure 2-
3A, CKOa), periodic third degree heart block (n=3/8), or second degree Type II heart block 
(n=3/8) (Figure 2-3A, CKOb). Overall, CKO mice have a significant increase in RR interval 
(Figure 2-3B), PR interval (Figure 2-3C), P-wave duration (Figure 2-3D), and QRS interval 
(Figure 2-3E). These EKG data from CKO mice are consistent with EKG findings in human 
DCM patients (Seidman and Seidman 2001; Towbin and Bowles 2006; Luk et al. 2009). The 
 33 
 
physiological studies further support that DOT1L deficiency in cardiomyocytes confers 
phenotypes similar to those observed in patients with DCM. 
 
Dot1L deficiency in cardiomyocytes down-regulates dystrophin expression  
Having established that DOT1L deficiency in cardiomyocytes causes phenotypes similar to 
those observed in DCM, we next attempted to understand the molecular mechanism. To date, 
mutations in over 30 genes have been linked to human DCM (Table S2-1) (Towbin and 
Bowles 2006; Karkkainen and Peuhkurinen 2007; Kimura 2008; Luk et al. 2009). Given that 
DOT1L-mediated H3K79 methylation is associated with actively transcribed genes (Martin 
and Zhang 2005; Wang et al. 2008b), we anticipated that one or more of the DCM-associated 
genes might be down-regulated due to loss of H3K79 methylation in the CKO heart. To this 
end, we performed four independent gene expression microarrays using the dual-color 
Agilent 4X44K Whole Mouse Genome Array system.  Data analysis revealed 751 down-
regulated probes representing 471 genes that are statistically significant with a false positive 
rate of 0.06%. Comparison of the microarray data with known DCM-associated genes 
identified two common genes, Titin (Ttn) and Dystrophin (Dmd).  
 
Ttn is a giant myofilament protein important for maintaining sarcomere structure and 
elasticity (Kostin et al. 2000).  Mutations in Ttn have been reported in autosomal dominant 
forms of familial DCM (Gerull et al. 2002). Mouse models expressing M-line deficient Ttn 
exhibit widened M-lines and gradual disassembly of sarcomeres, which lead to cardiac 
failure (Gotthardt et al. 2003; Weinert et al. 2006). If Ttn down-regulation is responsible for 
the DCM in CKO mice, we anticipate abnormal sarcomere structure in DOT1L CKO hearts. 
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However, TEM analysis revealed that sarcomere integrity is maintained in DOT1L CKO 
hearts (Figure S2-4), suggesting that down-regulation of Ttn is not a major contributing 
factor for the DCM in DOT1L CKO mice.  
 
Dmd was the first discovered DCM-associated gene that can cause both DCM and muscular 
dystrophy. Dmd is a membrane-associated protein that forms a dystrophin-glycoprotein 
complex (DGC), which connects contractile sarcomeres to the sarcolemma and extracellular 
matrix (ECM). This connection is vital for lateral force transduction between cardiomyocytes 
as well as for relieving mechanical stress on sarcolemma during contraction (Kostin et al. 
2000; Kimura 2008).  Since a loss of Dmd expression may be the cause of cell death and 
cardiac remodeling observed in CKO hearts, we first confirmed the microarray results by 
RT-qPCR. Data presented in Figure 2-4A demonstrate that the Dmd mRNA levels are down-
regulated to ~25% of the WT level in the CKO hearts. In contrast, expression of other 
randomly selected DCM-relevant genes (Actn2, Ldb3, Des, and Taz) was not significantly 
altered by DOT1L deficiency (Figure 2-4A). Consistent with a reduction at the RNA level, 
immunostaining revealed that Dmd protein level is also greatly diminished in CKO hearts 
(Figure 2-4B,C). Previous studies have demonstrated that mutations affecting expression of 
Dmd or any sarcoglycan (Sgc) gene lead to DGC instability and reduced levels of all 
complex proteins (Deconinck et al. 1997; Grady et al. 1997). Consistently, immunostaining 
revealed great loss of β-dystroglycan (βDG) and α-sarcoglycan (SGCA) proteins in CKO 
mice (Figure 2-4B, C) although none of the DGC components is altered at the RNA level by 
DOT1L deficiency (Figure 2-4A). These results suggest that loss of Dmd caused degradation 
of the DGC components, which in turn affects cardiomyocyte viability.   
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We next sought to determine whether DOT1L directly regulates Dmd expression in mouse 
heart by chromatin immunoprecipitation (ChIP). Despite extensive efforts, none of the home-
made or commercial DOT1L antibodies (Abgent: AP1198a, AP1198b; Cell Signaling: 
D8891, D8890; Abcam: ab7295) were able to detect endogenous DOT1L protein (data not 
shown); thus, unsuitable for ChIP. Therefore, we performed ChIP assays across the Dmd 
locus using an anti-H3K79me2/3 antibody. Results shown in Figure 2-4D demonstrate that 
relatively less H3K79me2/3 is observed upstream of Dmd transcription start site (TSS) but 
greatly increases downstream, continues to rise at 20kb downstream of TSS, and is still 
present as far as 59kb downstream of TSS. This H3K79me2/3 distribution pattern is 
consistent with published ChIP-seq results using various cell lines (Barski et al. 2007; Wang 
et al. 2008b). Importantly, the H3K79me2/3 enrichment on the Dmd gene depends on 
functional DOT1L as the enrichment is abolished when samples derived from Dot1L CKO 
hearts are used. In addition, the detected signals are specific as enrichment was not observed 
when IgG was used in a parallel ChIP assay. Previous studies have demonstrated that 
DOT1L-deficiency leads to a complete loss of H3K79 methylation (Jones et al. 2008), 
indicating DOT1L is the only H3K79 methyltransferase. The demonstration that H3K79 
methylation of the Dmd gene is dependent on functional DOT1L supports the notion that 
Dmd is a direct DOT1L target. 
 
It has been previously reported that Dmd expression is positively regulated by the binding of 
the transcription activator SRF (serum response factor) to a CArG box consensus sequence 
within the muscle-specific Dmd promoter (Galvagni et al. 1997). To examine whether 
transcription activation by SRF is affected in CKO hearts, we analyzed SRF RNA levels by 
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RT-qPCR. Results shown in Figure 2-4A demonstrate that SRF expression is not 
significantly altered in CKO hearts. In addition, ChIP analysis using an anti-SRF antibody 
indicates that SRF binding to the TSS or CArG box consensus region of Dmd is not affected 
by Dot1L knockout (Figure 2-4E). These results support that DOT1L and SRF function 
independently of each other and that transcriptional regulation of Dmd by DOT1L-mediated 
H3K79 methylation functions downstream of SRF.   
 
DOT1L directly regulates dystrophin expression in C2C12 cells 
To further demonstrate that DOT1L directly regulates Dmd expression we performed 
lentiviral shRNA knockdown (KD) and retroviral rescue experiments in C2C12 myoblast 
cells. KD of mDot1L effectively reduced both mDot1L and Dmd expression compared to 
control shRNA, whereas Srf is not significantly affected (Figure 2-4F). Despite similar 
expression levels of the WT and a catalytic mutant Flag-hDOT1L (Figure S2-5), Dmd 
expression is rescued only by WT Flag-hDOT1L, but not the catalytic mutant, indicating that 
DOT1L-mediated H3K79 methylation is critical for Dmd expression (Figure 2-4F). ChIP 
analysis demonstrates that the effect of DOT1L on Dmd expression is direct as both WT and 
catalytic mutant Flag-hDOT1L bind to the Dmd locus (Figure 2-4G). Consistent with 
transcriptional regulation of Dmd by DOT1L histone methyltransferase activity, H3K79 
methylation is also enriched at the Dmd locus in control shRNA and WT Flag-hDOT1L 
rescued samples, while enrichment is reduced in mDOT1L KD and catalytic mutant rescued 
cells (Figure 2-4H). Thus, these data establish that H3K79 methylation by DOT1L directly 
regulates Dmd transcription. 
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Postnatal dystrophin gene delivery and expression in cardiomyocytes rescues cardiac 
function in CKO mice  
Gene expression and ChIP analyses suggest that DOT1L’s role in cardiomyocytes may be 
mediated through its regulation of Dmd expression. To determine if Dmd is a key target 
contributing to the DCM phenotype, we performed in vivo rescue experiments using an 
adeno-associated virus serotype 9 (AAV9) vector expressing a minidystrophin gene under the 
control of CMV promoter. AAV-mediated gene therapy with minidystrophin has been 
previously shown to effectively treat dystrophic pathology (Wang et al. 2000).  The vector 
used to rescue Dot1L CKO mice, rAAV9-CMV-Dys∆3990 (rAAV9-miniDmd), provides 
high expression of minidystrophin in all muscle tissues including the heart (Wang et al. 
2008a). To rescue CKO mice, rAAV9-miniDmd was administered at two different age 
groups, either at P3 via intraperitoneal injection or at 2 months via tail vein injection and 
analyzed by ECHO. As shown in Table 2-2, cardiac function, EF and FS, are restored in 
CKO rescued mice injected at P3 (compare Tables 2-1 and 2-2). Additionally, increases in 
LVID, LV Vol and LV mass are significantly reduced by expression of minidystrophin 
(compare Tables 2-1 and 2-2). Similar improvements were also observed in adult mice 
rescued at 2 months of age (compare Tables 2-1 and 2-2). Most significantly, adult rescued 
mice are able to survive past the second stage of lethality with no impairments in cardiac 
function (Table 2-2, 8 months).  
 
In addition to ECHO analysis, EKG of rescued CKO mice was also analyzed. At 5 months 
during the second stage of lethality, EKG was obtained from mice rescued at P3. Results 
demonstrate that RR interval (Figure 2-5A), PR interval (Fig. 2-5B), P duration (Figure 2-
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5C), and QRS interval (Figure 2-5D) were restored in the CKO mice. For mice rescued as 
adults, EKG was analyzed at 5 months and 8 months of age. The RR interval (Figure 2-5E), 
P duration (Figure 2-5G), and QRS interval (Figure 2-5H) were restored in these mice, while 
PR intervals improved partially (Figure 2-5B, compare p-values with Figure 2-3C). In 
addition, heart blocks observed prior to injection were no longer present in rescued CKO 
mice as indicated by the EKG images and echocardiograms of the same mice before and after 
treatment (Figure S2-6A, B). Collectively, the above studies demonstrate that the functional 
defects caused by DOT1L deficiency in cardiomyocytes can be largely rescued by postnatal 
expression of Dmd, supporting that Dmd is a key DOT1L target in cardiomyocytes. 
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Discussion 
DOT1L is the only known H3K79 methyltransferase and is conserved from yeast to humans.  
It is highly expressed in the heart, blood cells, and testis although its expression in mammals 
is ubiquitously.  Germ-line knockout of Dot1L has been shown to be embryonic lethal with 
cardiovascular and hematopoietic defects. In this study, we demonstrate that DOT1L H3K79 
methyltransferase activity is vital for cardiac function in the mouse using a cardiac-specific 
knockout model.  DOT1L loss of function results in postnatal and adult lethality from dilated 
cardiomyopathy and congestive heart failure due to down-regulation of dystrophin (model in 
Figure 2-6). 
 
Dot1L CKO mouse is a useful model for understanding DCM 
Cardiac-specific loss of DOT1L H3K79 methyltransferase activity caused gross changes in 
cardiac growth and shape that are reminiscent of dilated cardiomyopathy.  DCM is a disease 
of the heart muscle characterized by enlargement of one or both heart chambers, eccentric 
hypertrophy, interstitial fibrosis, systolic dysfunction, and conduction defects. In this study, 
we show that Dot1L CKO mice hearts are spherical in shape with enlarged chamber volumes 
and increased mass.  Through immunostaining, we demonstrate that eccentric hypertrophy, 
increased proliferation, and reactive fibrosis may contribute to the increase in heart mass.  In 
addition, a significant increase in cellular apoptosis was observed in CKO hearts.  Finally, 
EKG and ECHO analysis revealed severe defects in cardiac force transmission and output. 
Collectively, these data support that loss function of DOT1L in cardiomyocytes results in 
phenotypes similar to those observed in DCM patients making our mouse a valuable model 
for understanding DCM. 
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Dystrophin is a key target mediating DOT1L function in the heart 
As the only known H3K79 methyltransferase, DOT1L is thought to play a genome-wide role 
in transcriptional regulation.  Therefore, it may be inferred that loss of DOT1L enzymatic 
activity would silence a large number of genes vital for cardiac function. Microarray analysis 
revealed 751 down-regulated probes corresponding to 471 genes in CKO hearts. However, 
only two of these genes have been directly linked to DCM in mouse and humans, Ttn and 
Dmd. Our histopathology data, including myocyte loss and remodeling, is consistent with a 
Dmd-deficiency (Heydemann and McNally 2007) and not loss of Ttn since sarcomeres 
remain normal.  
 
We demonstrate that cardiac Dmd expression correlates with DOT1L-mediated H3K79 
methylation. In addition, we show that DOT1L methyltransferase activity regulates Dmd 
transcription in C2C12 myoblast cells and that exogenous Flag-DOT1L is localized to the 
Dmd locus. Collectively, these data conclusively demonstrates that DOT1L is a 
transcriptional regulator directly involved in Dmd expression. While other genes regulated by 
DOT1L may contribute to the DCM phenotype observed in CKO mice, the fact that the 
cardiac functional defects can be rescued by expression of a minidystrophin supports that 
Dmd is a critical target mediating DOT1L function in the heart.  
 
In the mdx mouse, a nonsense mutation results in the loss of Dmd expression in all muscle 
cells.  Surprisingly, these mice do not develop severe DCM phenotypes (Hoffman et al. 
1987; Grady et al. 1997), while DOT1L deficiency caused Dmd down-regulation does.  Since 
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the DOT1L deficiency in CKO mice occurs only in cardiomyocytes, Dmd expression is 
retained in CKO skeletal muscle, allowing for normal levels of exercise.  The increased 
exercise in CKO mice compared to mdx mice causes additional workload and stress on the 
heart, which would escalate the severity of DCM.  Indeed, it has been reported that targeted 
repair in mdx mice using a skeletal-muscle restricted minidystrophin transgene significantly 
enhanced cardiac injury and DCM (Townsend et al. 2008).  
 
The apparent inconsistency between CKO and mdx mice can also be explained by the lack of 
a similar compensation mechanism. Previous studies have demonstrated that loss of Dmd 
expression in the mdx mouse is compensated by up-regulation of Utrophin (Utrn), an 
autosomal Dmd homolog (Deconinck et al. 1997; Grady et al. 1997).  However, this 
compensation mechanism does not seem to exist in CKO mice as DOT1L deficiency did not 
cause up-regulation of Utrn (Figure S2-7). Thus, the Dot1L CKO mouse may serve as a 
useful model for comparative analysis of the molecular mechanisms underlying the 
regulation of Utrn.   
 
A potential link between DOT1L and DCM/DMD 
Congestive heart failure is a common manifestation of cardiomyopathy, a disease caused by 
malfunction of the heart muscle (Seidman and Seidman 2001; Liew and Dzau 2004). DCM is 
the most common form of cardiomyopathy affecting 36.5 per 100,000 people (Seidman and 
Seidman 2001; Liew and Dzau 2004; Luk et al. 2009). Although extensive work has been 
performed to identify signature DCM genes through global expression profiling (Barrans et 
al. 2002; Barth et al. 2006; Camargo and Azuaje 2008), little effort has been focused on the 
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epigenetic contribution with the exception of histone acetylation (Zhang et al. 2002; Kook et 
al. 2003; Montgomery et al. 2007; Ha et al. 2010; Hang et al. 2010). With regard to histone 
methylation, only two studies have investigated changes in methylation patterns in heart 
failure (Movassagh et al. ; Kaneda et al. 2009). However, whether it directly contributes to 
the development of DCM is not known.  
 
The demonstration that loss of DOT1L enzymatic activity results in DCM not only 
establishes a connection between dysregulation of histone methylation to DCM, but also 
raises the possibility that malfunction of DOT1L might account for some DCM patients. To 
explore this possibility, we analyzed hDOT1L expression level in idiopathic DCM (n=27) 
and normal (n=11) myocardial samples from publically available microarray data 
(http://cardiogenomics.med.harvard.edu/project-detail?project_id=229). This analysis 
indicates that DOT1L is down-regulated in idiopathic DCM patients with all Affymetrix 
probe sets (n=11 probes per set) (Figure S2-8), supporting the notion that dysfunction of 
DOT1L may be a contributing factor to human idiopathic DCM. Mutations in Dmd is also 
the cause of both Duchenne and Becker Muscular Dystrophy (DMD and BMD, respectively), 
affecting 1 out of 3,500 males (Hoffman et al. 1987). Up to 90% of those patients manifest 
cardiomyopathies and many die of heart failure (Connuck et al. 2008). In this study, we 
established that DOT1L regulates Dmd expression in both cardiac and C2C12 cells, 
suggesting that a DOT1L-deficiency may contribute to DCM and human muscular 
dystrophy. Future studies should reveal whether DOT1L is genetically linked to DCM, 
DMD, and BMD in human patients. 
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Materials and Methods 
Generation of cardiac-specific Dot1L CKO mice. The targeting vector and generation of 
DOT1L chimeric mice has been described previously (Jones et al. 2008). DOT1L2lox/+ and 
DOT1L1lox/+ mice were mated with α-MHC-Cre+/+ transgenic mice to obtain DOT1L2lox/+;α-
MHC-Cre+/+ and DOT1L1lox/+;α-MHC-Cre+/+ mating pairs. Mice are kept on a 129SvJ, 
C57BL/6J mixed background.  DOT1L2lox/1lox;α-MHC-Cre+/+ mice and DOT1L2lox/2lox; α-
MHC-Cre+/+ mice were used as CKO mice. Upon Cre recombination, exons 5 and 6 are 
excised from the DOT1L locus. After splicing of the DOT1L transcript from the CKO allele, 
exons 4 and 7 of the mature mRNA are translated in-frame generating a mutant DOT1L 
protein lacking a portion of the SAM-binding motif. All mice procedures were performed 
following the guidelines set by the Institutional Animal Care and Use Committee. 
Echocardiography and electrocardiography. Experiments were performed at the Mouse 
Cardiovascular Models Core Facility at UNC-CH or in the lab of Dr. Xiao Xiao, UNC-CH. 
To restrain postnatal pups, paws are taped to a plastic board. For adult mice, soft cotton 
thread loops are placed around each leg, just proximal to the paw and gently snugged with a 
plastic slider. The distal ends of the threads are placed in notches cut into a plastic board and 
gently tightened to hold the animal in a supine position to prevent self-mutilation of the 
forelimbs. Warmed Aquasonic™ gel is applied over the thorax and a 30MHz probe is 
positioned over the chest in a parasternal position. Long and short axis B-mode and M-mode 
images are recorded. Upon completion of the procedure, the gel is wiped off and the animal 
is returned to its cage housed in a warm chamber. Time of restraint is 5 minutes or less. For 
electrocardiography, mice are anesthetized with inhaled isoflurane. Mice are taped to a 
warmed mouse board and their body temperature is monitored with a rectal probe and 
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maintained at 37+/-1 0C throughout the procedure. Thin (29 ga.) sharpened needle electrodes 
are passed subcutaneously into the area at the ventral base of each limb. After three leads are 
recorded, the needles are removed and the animals are allowed to recover. 
Histology and Immunofluorescence staining. For all tissue sectioning, beating hearts were 
harvested from euthanized mice and immediately transferred to ice cold PBS containing 1M 
KCl until the hearts stopped beating at diastole state. For H&E staining, hearts were fixed in 
4% paraformaldehyde overnight and paraffin embedded. Serial sections at 5 µm thickness 
were used for staining. Hearts used for all immunofluorescence staining were fixed in 4% 
PFA and subjected to sequential incubation with 10%, 20%, and 30% sucrose in PBS at 4ºC. 
Hearts were then flash frozen in OCT medium using liquid nitrogen and frozen serial 
sections of 5 µm thickness were prepared using a Leica Cryostat. Primary antibodies used for 
staining include anti-Dystrophin (Abcam; ab15277-500), anti-HSPG2 (Neomarkers; RT-
794), anti-a-Laminin (Chemicon; AB2034), anti-H3K79me2/3 (Abcam; ab2621-100), anti-
Ki-67 (Abcam; ab15580). Secondary antibodies used are Alexa Fluor 594 goat anti-rat IgG 
(Invitrogen; A21212), Alexa Fluor 594 donkey anti-rabbit IgG (Invitrogen; A21207), Alexa 
Fluor 488 donkey anti-rabbit IgG (Invitrogen; A21206). Sections were counterstained with 
DAPI. 
TUNEL assay. TUNEL staining was performed on frozen sections using the ApopTag 
Fluorescein In Situ Apoptosis Detection Kit (Millipore; S7110) and counterstained with 
DAPI. 
Masson’s Trichrome Staining.  Paraffin sections, 5 µm thick, of hearts from 5 month old 
mice were used for staining. Masson’s Trichrome Stain Kit was purchased from Dako 
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(AR173) and procedures were followed according to manufacturer’s specifications manually, 
without an Artisan staining system. 
Transmission Electron Microscopy. WT and CKO mice were injected with 25U heparin 
i.m. prior to euthanasia by isofluorane overdose. The hearts were quickly exposed, and 
perfused with 3 mg/ml 2,3-Butanedione monoxime in Hepes-buffered Krebs solution, 
followed by perfusion with 2% glutaraldehyde plus 6% sucrose in 75 mM Na-Cacodylate 
buffer (pH 7.4) supplemented with 3 mg/ml BDM and 0.1% tannic acid, followed by 2% 
osmium tetroxide. Samples were stained with uranyl acetate en bloc. Images were acquired 
on a Zeiss EM 910 transmission electron microscope utilizing a Gatan SC1000 digital 
camera. 
Microarray and RT-qPCR analysis. Hearts were flash frozen in liquid nitrogen and ground 
to a fine powder. Total RNA was purified from tissue powder using Qiagen RNeasy Kit. 
RNA from three hearts, 1ug each, was pooled together. Four pairs of pooled RNA, 
representing a total of 12 WT and 12 CKO hearts, were used for gene expression analysis. 
Samples were submitted to the UNC Genomics and Bioinformatics Core Facility for RNA 
labeling, amplification, hybridization, and scanning. The dual-color Agilent 4X44K Whole 
Mouse Genome Array system was used. All reagents were purchased from Agilent and 
procedures were followed according to Agilent’s protocols. Raw data was uploaded into the 
UNC Microarray Database (Agi-Scanner-Reg-MM-4X44K-D20060807-BARCODE14868; 
Slide Run US82800149). Data was analyzed using the SAM algorithm (Tail strength 51.4%, 
se 63.8%) to yield 1379 significant probes with a Median number of false positives = 0.81 
and false discovery rate of 0.06%. For RT-qPCR analysis, RNA prepared above was treated 
with DNase I, and first-strand DNA synthesis was performed using Improm II (Promega). 
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SYBR GreenER qPCR SuperMix (Invitrogen) was used for qPCR.  Relative expression was 
normalized to gapdh. Primers are shown in Table S2-2. 
Micro-Chromatin Immunoprecipitation and Western blot. Micro ChIP from frozen heart 
biopsies was performed as described previously (Dahl and Collas 2008) with the following 
modifications. Frozen hearts from P10 pups were ground to a fine powder prior to 
formaldehyde cross-linking. DNA was fragmented into 300-500 bp by sonication at 15% 
power (2X15 sec, 0.5 sec on and 2 sec off). Immunoprecipitation was performed using anti-
H3K79me2/3 (Abcam) and anti-Rabbit IgG (Santa Cruz; sc-2027). ChIP’ed samples were 
washed twice with low salt (140 mM NaCl) RIPA buffer, once with high salt (500 mM 
NaCl) RIPA buffer, and twice with TE buffer. DNA was purified using the Chelex-100 
method and qPCR was performed using the ChIP primers listed in Table S2-2. For Western 
blot analysis, P1 frozen hearts were ground to a fine powder for histone extraction and 
Western blot as described previously (Fang et al. 2002).  
C2C12 knockdown and rescue. C2C12 cells were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% FBS and 1% penicillin/streptomycin.  To establish 
stable KD cell lines, the lentivirus pTY-EF1a system was used as described previously (Cao 
et al. 2008; He et al. 2008). To knockdown mDOT1L, a shRNA 19mer was designed 
targeting the coding region (5’- GGAGCCAGATCTCAGAGAA-3’). The control shRNA is 
targeted against a bacterial protein with no mouse or human homology (5’- 
GTTCAGATGTGCGGCGAGT-3’). KD cells were selected and maintained in media 
containing 2µg/mL puromycin. For rescue experiments, KD cells were infected with 
retrovirus expressing WT and catalytic mutant Flag-tagged human DOT1L (Flag-hDOT1L) 
as described previously (Okada et al. 2005). Retrovirus infected cells were selected and 
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maintained in media containing 2µg/mL blasticidin. RNA was isolated using RNeasy Kit 
from Qiagen. The same micro-ChIP procedure described above was followed for ChIP using 
50,000 cells per sample. Dynabeads Protein A and M2 Flag antibody  (Sigma; F3165) were 
also used. 
Postnatal rescue of CKO mice with rAAV-miniDmd.  The functional miniature version of 
human dystrophin gene ∆3990 (miniDmd) under the transcriptional control of CMV 
promoter has been described previously (Wang et al. 2000). The miniDmd gene expression 
cassette was packaged into adeno-associated virus (AAV) serotype 9 vector using the helper-
free, triple plasmids transfection method and purified by double CsCl density 
ultracentrifugation (Xiao et al. 1998). The rAAV9-CMV-miniDmd titers were determined by 
DNA dot blot at approximately 1 x 1013 viral genome (v.g) particles per ml. For 3-day-old 
neonatal CKO mice, a single dose of 1 x 1011 v.g./mouse in 50 µl was injected 
intraperitoneally (i.p). For 2-month-old CKO mice, a single dose of 1 x 1012 v.g./mouse in 
600 µl was injected via tail vein (i.v.). 
Statistics. Indicated p-values were calculated using two-tailed t-test. 
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Figure 2-1. Disruption of DOT1L function in mouse cardiomyocytes results in heart 
dilation and lethality. (A) Dot1L CKO in mouse heart causes postnatal and adult lethality. 
Survival curves of WT, HET, and CKO mice.  Fifty percent of CKO mice die within the first 
2 wks after birth and the remaining 50% die by 6 months of age. (B) CKO hearts are severely 
enlarged compared to WT. Shown are WT and CKO hearts harvested from P10 and 5 month 
adult mice, respectively. Scale bar=1mm. (C) H&E staining of paraffin tissue sections 
indicated that CKO hearts are enlarged due to ventricular chamber dilation. Scale bar=1mm. 
(D) CKO mice have increased heart to body weight ratios. Heart weight (mg) to body weight 
(g) ratios were calculated using an analytical balance. CKO mice have increased ratios 
compared to WT littermates; * p<0.06, ** p<0.006, *** p<0.0006. (E) CKO mice have 
increased heart weight. Heart weight (mg) was measured using an analytical balance. * 
p<0.06.  
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Figure 2-2. Disruption of DOT1L function in mouse cardiomyocytes results in 
pathologic cardiac remodeling. (A) Positive TUNEL staining (green) merged with DAPI 
(blue) demonstrates increased cell death in CKO hearts (P10, Scale bar=5 µm). (B) TEM 
analysis of P10 hearts demonstrates increased autophagic cell death (compare i. and ii.; 
yellow box is enlarged from ii.; vacuoles indicated by yellow arrows; scale bar=2 µm) and 
myofibroblast infiltration (indicated by * in iii) in CKO hearts. Note that myocytes in WT 
hearts show tight lateral association, whereas myocytes in CKO hearts have large gaps due to 
myofibroblasts infiltration. (C) Increased interstitial ECM, indicated by staining of the ECM 
component HSPG2 (red), is observed in the CKO hearts (arrowheads). Increased ECM and 
myofibroblasts lining the inner left ventricular chamber wall (between the two yellow lines) 
is also observed in CKO hearts. Scale bar=10 µm. (D) Masson’s trichrome staining of 
paraffin tissue sections of mouse hearts (5 Mo. old).  Two enlarged regions are shown (black 
and yellow boxes).  Interstitial fibrosis is seen in CKO hearts but not in WT counterparts. 
Scale bar=5 mm. (E) RT-qPCR analysis demonstrates activation of fetal-specific genes 
(Myh7, Acta1, Nppa, and Nppb) in the CKO hearts. In contrast, down-regulation of adult 
Myh6 is also observed. (F) Increased cell proliferation in CKO hearts (P1 and P5). Frozen 
tissue sections were stained with anti-Ki-67, a marker of cell proliferation, and 
counterstained with DAPI.  The percentage of proliferating cells were calculated by dividing 
the number of Ki-67 positive nuclei by total nuclei and multiplying by 100. 
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Figure 2-3. Disruption of DOT1L function in mouse cardiomyocytes results in 
conduction abnormalities. (A) Representative electrocardiography for WT and CKO mice. 
The analysis was performed using 5 month old mice (n=8 per group). CKOa has complete 
AV dissociation as evidence by non-sustained ventricular tachycardia, while CKOb has a 
Type II second-degree heart block. Scale bar=200 ms. (B-E) Quantification of ECG data 
indicated an overall significant increase in RR interval (B), PR interval (C), P-wave duration 
(D), and QRS interval (E). p-values calculated by student t-test. 
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Figure 2-4. Dystrophin is a direct target of DOT1L. (A) RT-qPCR analysis using RNAs 
isolated from P10 WT and CKO hearts (n=12). Dmd and Ttn expression is down-regulated in 
Dot1L CKO hearts. Other members of the dystrophin-glycoprotein complex (Dag1, Sgca, 
Sgcb, Sgcd, and Sgcg) as well as selected DCM causal genes (Actn2, Ldb3, Des, and Taz) 
remain unchanged. (B-C) Immunostaining of frozen heart sections demonstrated loss of Dmd 
protein in CKO hearts (green). Consistent with a Dmd-deficiency and complex instability, 
reduction of βDG (B) and SGCA (C) is observed.  (D) Micro-ChIP using heart tissues from 
P10 pups demonstrates that H3K79me2/3 is enriched in the gene body of Dmd, and the 
enrichment is dependent on functional DOT1L. Amplicon #1 located about 15 kb upstream 
of TSS serves as background for H3K79me2/3 enrichment. (E) ChIP using an anti-SRF 
antibody demonstrates that SRF binding to the CArG box consensus region of the Dmd 
muscle-specific promoter is not affected in Dot1L CKO hearts. Amplification at -15kb TSS 
serves as a background for SRF enrichment. (F) RT-qPCR analysis demonstrates that Dot1L 
knockdown in C2C12 cells results in down-regulation of Dmd. Error bars represent s.d. of 
three independent experiments. (G,H) ChIP analysis demonstrates binding of F-DOT1L to 
the Dmd locus and its methylation on H3K79 is dependent on DOT1L enzymatic activity. 
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Figure 2-5. Rescue of electrical conduction in CKO mice by expression of 
minidystrophin gene. (A-D) The defective function of CKO heart can be rescued by 
expression of a mini-dystrophin gene when injected at P3 and analyzed at 5 months of age as 
indicated by the lack of significant difference between WT and CKO rescued mice. (E-H) 
Additionally, minidystrophin can rescue adult CKO mice injected at 2 months in terms of RR 
interval (E), P-wave duration (G), and QRS interval (H). In addition, PR interval (F) was 
partially rescued as the difference observed is less than without miniDmd. (p=0.02 in rescue 
vs *** p<0.0006 in without rescue at 5 months). At 8 months of age, past the second stage of 
lethality, CKO+miniDmd mice still maintain similar rescued levels of electrical conduction 
performance (E-F). 
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Figure 2-6. Model for role of DOT1L in regulating dystrophin transcription and cardiac 
function. DOT1L-mediated H3K79 methylation is required for active transcription of the 
dystrophin locus. In the absence of DOT1L enzymatic activity, dystrophin is silenced, 
resulting in reduced protein levels and destabilization of the DGC complex. Without DGC, 
sarcolemma damage, cell death, and reduced myocardial performance occur. Compensatory 
remodeling and chamber dilation is observed in an attempt to repair cardiac performance. 
However, this becomes maladaptive and is manifested by dilated cardiomyopathy and heart 
failure. 
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Table 2-1. Heart function of WT and CKO mice as measured by Echocardiography. 
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Table 2-2. Heart function of rAAV-miniDmd rescued CKO mice as measured by 
Echocardiography. 
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Figure S2-1. DOT1L expression in mouse heart tissue. (A) The Dot1L conditional allele 
contains a promoterless b-geo cassette. LacZ staining was performed to analyze Dot1L 
expression in mouse tissues. As shown, Dot1L is highly expressed in the heart. (B) RT-qPCR 
analysis of heart RNA extracts during embryonic development indicates that Dot1L 
expression peaks after birth. Relative expression normalized to Gapdh and expression at 
E10.5 set to 1. 
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Figure S2-2. Generation of cardiac-specific DOT1L CKO mice. (A) Schematic diagram 
of Dot1L locus to generate cardiac conditional knockout (CKO) by crossing DOT1L2lox/+ and 
DOT1L1lox/+ mice with α-MHC-Cre mice. The DOT1L2lox/+ conditional allele contains loxP 
sites (triangles) flanking Exons 5 and 6. Primer pairs DF1 and DR1 were used for 
genotyping, RTa and RTb were used for RT-qPCR analysis. (B) Diagram of DOT1L WT and 
CKO protein that harbors a deletion of 108 aa in the SAM binding motif (+, positive-charged 
region; NES, nuclear export signals; LZ, leucine zipper motif). (C) Dot1L CKO mice are 
born at Mendelian ratio from intercrosses of heterozygote mice (DOT1L2lox/+;α-MHC-Cre 
with DOT1L1lox/+;α-MHC-Cre). (D) RT-qPCR analysis confirms efficient recombination at 
Dot1L locus in P1 CKO hearts. (E) Western blot analysis demonstrates loss of H3K79me2/3 
in CKO P1 heart histone extracts. (F) Immunostaining of frozen mouse heart sections (5 µm 
thick) with anti-H3K79me2/3 (red) demonstrates loss of H3K79me2/3 in CKO hearts. The 
sections were counterstained with DAPI (blue). 
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Figure S2-3. Concentric hypertrophy does not contribute to increased CKO heart mass. 
(A) Body weights of WT and CKO mice were measured (g) using an analytical balance. No 
significant difference in body weights was observed between WT and CKO littermates. (B) 
No significant difference in the size of WT and CKO cardiomyocytes is observed. Frozen 
tissue sections were stained with anti-Laminin and cardiomyocyte circumference measured 
(pixels) using ImageJ software. The average circumference with s.d. are shown with the 
number of cells measured per sample indicated. (C) Representative images of cardiomyocyte 
cross-sections visualized by anti-Laminin staining. 
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Figure S2-4. Sarcomere integrity remains intact in CKO hearts. Sections from P10 
perfused hearts were analyzed by TEM. The overall sarcomere length and structure appears 
normal in CKO mice and do not exhibit the defects observed in Ttn-deficient hearts. 
Representative image of each genotype is shown. 
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Figure S2-5. Expression level of human DOT1L rescue constructs. WT and catalytic 
mutant, Mut, retrovirus constructs are expressed at similar levels in shRNA KD cells. 
Relative expression was normalized to mouse Gapdh and background level of hDOT1L 
primers in shRNA sample was set to one. 
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Figure S2-6. Heart blocks absent in adult rescued CKO mice. Representative EKG (A) 
and echocardiogram (B) images of the same mice taken from an ECHO machine before and 
after tail vein injection with rAAV9-miniDmd. The data indicates that a heart block observed 
before the injection is alleviated by 5 months of age. 
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Figure S2-7. Utrophin expression is not up-regulated in CKO hearts. RT-qPCR was 
performed to compare Utrn RNA levels in WT and CKO hearts (n=12 per genotype). 
Relative expression is shown, normalized to Gapdh. 
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Figure S2-8. hDOT1L is down-regulated in human idiopathic DCM myocardia. 
hDOT1L expression level was analyzed from a publically available microarray database 
(CardioGenomics). The database represents myocardial samples from patients undergoing 
heart transplantation with different etiologies as well as “normal” organ donors whose hearts 
could not be used for transplants. Gene expression microarray was performed using 
Affymetrix Human Genome U133 Plus 2.0 Array. Data from three different probe sets for 
hDOT1L is shown. Each probe set consists of 11 different probes. p-Values were calculated 
using two-tailed t-test. 
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Table S2-1. Genes with DCM-associated mutations. 
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Table S2-2. RT-qPCR and ChIP-qPCR primer sequences. 
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DOT1L IS REQUIRED FOR MLL-AF9 LEUKEMOGENESIS 
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Abstract 
Chromosomal translocations of the MLL, mixed lineage leukemia, gene are a common cause 
of acute leukemias. The oncogenic function of MLL fusion proteins is partly mediated 
through aberrant up-regulation of Hoxa and Meis1 genes. Here we use a tamoxifen-inducible 
Cre mouse model to demonstrate that DOT1L, the H3K79 methyltransferase, is required for 
both initiation and maintenance of MLL-AF9 induced leukemogenesis in vitro and in vivo. 
Through gene expression and ChIP analysis we demonstrate that mis-targeting of DOT1L, 
subsequent H3K79 methylation, and up-regulation of Hoxa and Meis1 genes underly the 
molecular mechanism of how DOT1L contributes to MLL-AF9 mediated leukemogenesis. 
Our provides the first in vivo evidence for the function of DOT1L in leukemia and reveals the 
molecular mechanism for DOT1L in MLL-AF9 mediated leukemia. Thus, DOT1L may serve 
as a potential therapeutic target for the treatment of leukemia caused by MLL translocations. 
 
 80 
 
Introduction 
MLL1 (mixed lineage leukemia 1) is a SET domain-containing protein, capable of 
methylating histone H3 lysine 4 (H3K4), which correlates with transcriptional activation 
(Martin and Zhang 2005; Kouzarides 2007). One important function of MLL is to maintain 
the “on” state of homeobox (Hox) gene expression during embryonic development and 
hematopoiesis (Guenther et al. 2005). The full-length MLL1 precursor protein is 
proteolytically cleaved by Taspase1 to generate N-terminal 300kDa (MLL1N) and C-
terminal 180kDa (MLL1C) proteins that form a heterodimer as part of a multi-subunit 
protein complex (Hsieh et al. 2003a). Previous studies indicated that MLL dimerization is 
required for its stability as well as proper spatio-temporal activation of Hox gene expression 
(Hsieh et al. 2003a; Hsieh et al. 2003b).  
 
The gene that encodes human MLL1 is located at 11q23 and harbors an 8.3kb breakpoint 
cluster region, which is known to be involved in chromosomal rearrangements with over 50 
different genes (Ayton and Cleary 2001; Hess 2004). Translocation of MLL is a common 
cause of acute leukemias, accounting for 5-10% of adult acute myeloid leukemia (AML) and 
acute lymphoid leukemia (ALL). Of these MLL-related leukemias, 10% are secondary 
cancers caused by chemotherapy (Daser and Rabbitts 2004). Strikingly, MLL rearrangements 
also account for ~80% of ALL and ~60% of AML in infants (Ayton and Cleary 2001; Hess 
2004). In MLL-related leukemias, genes of the Hoxa cluster are frequently up-regulated, and 
their sustained expression is required for leukemic stem cell (LSC) maintenance 
(Argiropoulos and Humphries 2007).  
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The MLL N-terminus retained in oncogenic fusion proteins lack the enzymatic SET domain, 
but maintain two DNA-binding domains (AT-hooks and DNMT homology region) and 
subnuclear localization motifs (Li et al. 2005).  Thus, MLL-fusion proteins are likely directed 
to MLL gene targets, and heterodimerization with wild type MLL1C expressed from the non-
rearranged allele confers Hoxa gene activation. Meanwhile, the translocation partner proteins 
also contribute to maintaining gene expression either through intrinsic transcriptional 
activation activity or recruitment of other effector molecules (Krivtsov and Armstrong 2007).  
 
Among the ~50 different MLL fusion partners, AF4, AF9, AF10, and ENL account for over 
2/3 of all MLL-related leukemias and have been reported to associate with each other 
through direct or indirect protein-protein interactions (Erfurth et al. 2004; Zeisig et al. 2005; 
Krivtsov and Armstrong 2007). AF4 and AF9 are serine/proline rich nuclear proteins with 
transcriptional activation domains and directly interact with one another. Not only does AF4 
associate with AF9, it also binds directly to ENL. ENL belongs to a family of proteins which 
contain a YEATS domain responsible for H3 binding and association with histone-modifying 
complexes. In addition, ENL interacts with AF10, and AF10 co-localizes with AF4 (Slany 
2005; Zeisig et al. 2005; Krivtsov and Armstrong 2007). Recently, AF4, AF9, and ENL were 
shown to be components of a large protein complex named AEP (Yokoyama et al. 2010) or 
EAP (Bitoun et al. 2007), which also contain the transcription elongation factor P-TEFb.  
 
Yeast Dot1 (disruptor of telomeric silencing) and its mammalian homolog DOT1L methylate 
Lysine 79 within the globular domain of histone H3 (H3K79) (Feng et al. 2002; Lacoste et al. 
2002; van Leeuwen et al. 2002). Although Dot1 was originally identified as a regulator of 
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telomeric silencing (Singer et al. 1998), data suggest that Dot1-mediated H3K79 methylation 
is linked to euchromatic gene transcription (Schubeler et al. 2004; Steger et al. 2008) and 
transcription elongation. A recent study indicates that DOT1L exists in a large protein 
complex that regulates expression of Wingless target genes (Mohan et al. 2010). 
Additionally, DOT1L has been shown to regulate erythroid differentiation during embryonic 
hematopoiesis (Feng et al. 2010).  
 
Using in vitro methylcellulose re-plating assays, we have shown that mis-targeting of 
DOT1L and dysregulation of MLL-target genes contributes to leukemogenesis in MLL-AF10 
and CALM-AF10 (Okada et al. 2005; Okada et al. 2006). Similar in vitro studies were also 
reported for leukemic transformation caused by MLL-ENL (Mueller et al. 2007) and MLL-
AF4 (Krivtsov et al. 2008). Interestingly, DOT1L was previously shown to be part of the 
EAP complex (Bitoun et al. 2007; Mueller et al. 2009). These data raise the possibility that 
DOT1L interaction with MLL-fusion proteins and aberrant targeting to gene loci may be a 
universal mechanism mediating MLL leukemogenesis. To further substantiate the role of 
DOT1L in leukemia, we generated a conditional DOT1L knockout mouse model and 
evaluated the role of DOT1L in MLL-AF9-mediated leukemogenesis. Our studies not only 
establish a critical function of DOT1L in the initiation and maintenance of leukemia in vivo, 
but also demonstrate a role for DOT1L in the activation of leukemia genes such as Meis1 and 
the Hoxa cluster. 
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Results 
DOT1L is required for MLL-AF9-induced transformation in vitro 
Previous studies had only analyzed the role of DOT1L in MLL-mediated leukemogenesis in 
vitro (Okada et al. 2005; Okada et al. 2006; Mueller et al. 2007; Krivtsov et al. 2008), and the 
pathophysiological relevance of those data need to be confirmed in vivo. To this end, we 
generated an inducible knockout system by crossing mice harboring a Dot1L conditional 
allele (DOT1l2lox) (Jones et al. 2008) with mice harboring a Cre-recombinase-Oestrogen-
Receptor-T2 allele (Cre-ERT2) at the ubiquitous ROSA26 locus (Ventura et al. 2007). Upon 
tamoxifen (TAM) administration, the Cre-ERT2 system allows for translocation of Cre-
recombinase into the nucleus, resulting in efficient recombination of genomic loxP sites 
(Ventura et al. 2007). Previous studies have confirmed that Cre-recombination of the DotL 
allele removes exons 5 and 6, which encode part of the SAM binding motif required for 
enzymatic activity, to generate the DOT1l1lox null allele, abolishing all H3K79 mono-, di-, 
and tri-methylation (Jones et al. 2008). 
 
Using this inducible system, we first investigated the role of DOT1L in the initial 
transformation of hematopoietic progenitor cells (HPCs) by expression of MLL-AF9. FACS 
sorted c-Kit+ HPCs from bone marrow of conditional DOT1L2lox/1lox;Cre-ERT2 (2l/1l) and 
control DOT1Lwt/wt;Cre-ERT2 (wt/wt) mice (Figure 3-1B) were infected with retroviruses 
expressing MLL-AF9 or empty vector control. After infection, cells were treated with TAM 
for 7 days and efficient deletion of Dot1l was confirmed by RT-qPCR (Figure 3-1C). To 
evaluate the effect of DOT1L depletion on MLL-AF9 mediated transformation, infected 2l/1l 
and wt/wt cells were subjected to serial methylcellulose re-plating, which selects for self-
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renewing cells. As shown in Figure 3-1D, no colonies were observed by the second and third 
round in DOT1L depleted cells, suggesting that DOT1L is required for initial transformation 
by MLL-AF9.  
 
DOT1L is required for MLL-AF9-mediated leukemogenesis in vivo 
We next asked whether DOT1L is required for MLL-AF9 mediated leukemogenesis in the 
mouse via bone marrow transplantation (BMT). In our system, donor 2l/1l and wt/wt mice 
are maintained on a 129Sv/Jae and C57/B6 Ly5.2 mixed background, while recipient mice 
are maintained on a C57/B6 Ly5.1 background. Thus, donor leukemic cells (LCs) can be 
distinguished from wild-type recipient and radio-protector cells, which do not contain the 
Dot1L conditional allele or Cre-ERT2 allele, by fluorescence activated cell sorting (FACS). 
Donor MLL-AF9 LCs, collected from the third round of methylcellulose re-plating, were 
mixed with radio-protector Ly5.1/Ly5.2 BMCs at a 1:5 ratio and transplanted into recipient 
mice. TAM administration was initiated three weeks post-BMT, prior to the detection of LCs 
in bone marrow (Figure 3-2E), to induce Dot1L recombination in donor LCs. RT-qPCR 
analysis confirmed efficient deletion of Dot1L by the TAM treatment (Figure S3-1). As 
expected, all mice transplanted with wt/wt MLL-AF9 LCs died by 14 weeks post-BMT 
(Figure 3-2B). However, TAM treatment increased survival of mice transplanted with 2l/1l 
MLL-AF9 LCs (Figure 3-2B). The extended life span of the 2l/1l MLL-AF9 TAM treated 
group (red dotted line) is not due to other effects of TAM as only a 1-2 weeks increase in 
survival was observed between treated and untreated wt/wt MLL-AF9 (Figure 3-2B, dotted 
and solid black lines). Consistent with increased survival, TAM treatment prevented 
splenomegaly (Figure 3-2C) and leukemia infiltration of liver (Figure 3-2D) in mice that 
 85 
 
received 2l/1l MLL-AF9 LC transplantation, but not to those receiving wt/wt MLL-AF9 LCs. 
Furthermore, FACS analysis demonstrates that donor wt/wt MLL-AF9 LCs constituted a 
third (or 58%) of the bone marrow population at 6 weeks (or 9 weeks) post-BMT, whereas 
no 2l/1l MLL-AF9+TAM LC donor cells were detectable (Figure 3-2E-F), indicating that the 
ability of MLL-AF9 LCs to repopulate the recipient bone marrow requires functional 
DOT1L. Strikingly, by 24 weeks post-BMT no 2l/1l MLL-AF9 LCs are detected in the 
peripheral blood of TAM treated mice (Figure 3-2G), demonstrating that MLL-AF9 LCs fail 
to establish AML in the absence of DOT1L.  Collectively, these results demonstrate a critical 
function for DOT1L in the initiation of leukemia in vivo.  
 
DOT1L is required for maintaining MLL-AF9 leukemic transformation in vitro 
Having established the function for DOT1L in the initiation of leukemia, we next asked 
whether DOT1L is also required for maintaining the leukemic state induced by MLL-AF9. 
To this end, MLL-AF9 LCs were propagated in liquid culture in the presence or absence of 
TAM for a period of 7 days. After verification of efficient TAM-induced Dot1l 
recombination by genotyping (Figure 3-3B) and RT-qPCR (Figure 3-3C), an equal number 
of cells were plated onto methylcellulose.  MLL-AFX LCs were used as a negative control 
since DOT1L was previously shown not to be required for maintaining transformation 
induced by MLL-AFX (Okada et al. 2005). Results shown in Figure 3-3D demonstrate that 
2l/1l MLL-AF9 transformed cells failed to produce colonies upon TAM-induced depletion of 
DOT1L. In contrast, similar treatment exhibited no effect on MLL-AFX transformed cells, 
indicating that depletion of DOT1L did not cause a general cytotoxic effect. Additionally, 
TAM treatment by itself had no effect on wt/wt LC colony formation potential (Figure 3-3D). 
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This study demonstrates that MLL-AF9 transformed cells require DOT1L for maintaining 
leukemic self-renewal in vitro. 
 
DOT1L is required for MLL-AF9-induced acute leukemia progression in vivo 
The in vivo results in Figure 3-2E-J suggest that DOT1L is required for MLL-AF9 
leukemogenesis. In those experiments, TAM administration was initiated at 3 weeks post-
BMT. At this stage, acute leukemia has yet to develop since donor LCs in the bone marrow 
were undetectable by FACS (Figure 3-2E). To investigate the importance of DOT1L in the 
maintenance of MLL-AF9-induced acute leukemia in vivo, we administrated TAM at 6 
weeks post-BMT when the transplanted LCs account for ~30% of the bone marrow 
population (Figure 3-2F). At 9 weeks post-BMT, TAM-induced DOT1L depletion greatly 
reduced splenomegaly (Figure 3-4B) and liver infiltration (Figure 3-4C) in 2l/1l MLL-AF9 
mice. FACS analysis of recipient bone marrow revealed that 2l/1l MLL-AF9 LCs 
represented a lower percentage of total BMCs in treated mice compared to untreated controls 
(Figure 3-4D; 44.2% vs 60.7% at 9 weeks; 27.9% vs 83.0% at 12 weeks). In TAM treated 
mice, we also observed a decrease in 2l/1l MLL-AF9 donor LCs at 12 weeks compared to 9 
weeks post-BMT (Figure 3-4D; 27.9% vs 44.2%). In contrast, the percentage of wt/wt donor 
LCs increased from 60.7% to 83.0% in the same period (Figure 3-4D). Moreover, FACS 
analysis indicated that the remaining DOT1L deficient donor LCs at 12 weeks expressed 
lower levels of stem cell/progenitor cell marker c-Kit (Figure 3-4D), indicating a depletion of 
clonogenic leukemic progenitor/stem cells in the absence of DOT1L.  
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To analyze the effect of in vivo DOT1L deficiency on the self-renewal capacity of LCs, we 
sorted donor LCs at 12 weeks post-BMT and plated equal numbers onto methylcellulose. 
Results shown in Figure 3-4E demonstrate that the colony formation capacity of 2l/1l LCs 
from TAM treated mice is greatly reduced. Although colonies were observed after the first 
round of plating, those cells failed to give rise to additional colonies after the second round. 
In contrast, wt/wt LCs have increased colony formation capacity (Figure 3-4E). Thus, TAM-
induced DOT1L depletion in vivo blocks AML progression by disrupting MLL-AF9 LC self-
renewal capacity, which is consistent with the decreased c-Kit expression (Figure 3-4D).   
 
Loss of DOT1L function causes cell cycle arrest in MLL-AF9-induced leukemic cells 
Previous studies have shown that loss of DOT1L induces cell cycle arrest in ES cells (Jones 
et al. 2008; Barry et al. 2009) and erythroid cells (Feng et al. 2010).  To analyze the effect of 
DOT1L on cell proliferation, we cultured LCs in liquid media in the presence or absence of 
TAM.  Results shown in Figure 3-5A demonstrate that loss of DOT1L inhibits proliferation 
of cells transformed by MLL-AF9, but not cells transformed by MLL-AFX, indicating that 
depletion of DOT1L did not cause a general cytotoxic effect. FACS analysis of cells stained 
with propidium iodide demonstrates that MLL-AF9 LCs arrest at G0/G1 after DOT1L 
depletion, while no effect on cell cycle progression was observed for MLL-AFX LCs (Figure 
3-5B). General cytotoxic effects from TAM treatment were not responsible for the cell cycle 
arrest as no effect was observed with wt/wt MLL-AF9 LCs (Figure 3-5A-B). Consistent with 
a G0/G1 arrest, substantial up-regulation of two regulators of G1 progression, pRb and the 
CDK inhibitor p16 (Lukas et al. 1995; Medema et al. 1995), was detected in 2l/1l MLL-AF9 
LCs upon loss of DOT1L (Figure 3-5C). Since H3K79 methylation is generally linked to 
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transcription activation, DOT1L loss of function is expected to down-regulate direct gene 
targets of DOT1L. Therefore, the observed up-regulation of p16 and pRb expression is likely 
to be an indirect consequence.  
 
DOT1L regulates expression of Hoxa cluster and Meis1 
Previous studies have shown that the Hoxa gene cluster is up-regulated in MLL-AF9 LSCs 
(Krivtsov et al. 2006; Somervaille and Cleary 2006). To determine whether DOT1L is 
involved in Hoxa genes up-regulation, we analyzed their expression by RT-qPCR. We found 
that all analyzed Hoxa genes are up-regulated in MLL-AF9 transformed cells when 
compared to normal HPCs (Figure 3-6A). Importantly, DOT1L plays a crucial role in 
activation of the Hoxa cluster as TAM-induced DOT1L depletion resulted in their down-
regulation (Figure 3-6A). In addition, two Hoxa co-factors, Meis1 and Pbx3, required for 
maintaining MLL-AF9 leukemic stem cell potential (Wong et al. 2007), are also down-
regulated in response to TAM-induced DOT1L depletion (Figure 3-6A). Studies have shown 
that in addition to their role in maintaining LSC identity, continued Hoxa and Meis1 
expression also help block differentiation (Somervaille and Cleary 2006; Muntean et al. 
2010). Accordingly, Csf3r and Ltf, genes associated with myeloid differentiation and down-
regulated in MLL-AF9 LCs, are re-activated upon TAM-induced DOT1L deletion (Figure 3-
6B). These data support the notion that DOT1L is required for maintaining a transcriptional 
program that supports LSC self-renewal and blocks differentiation. 
 
Next, chromatin immunoprecipitation (ChIP) was performed to determine whether DOT1L is 
directly targeted to Hoxa and Meis1 loci to regulate their expression in MLL-AF9 LCs. 
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Because no ChIP-grade DOT1L antibody is available, we used an antibody that recognizes 
H3K79 di- and tri-methylation (H3K79me2/3; Abcam), modifications deposited by DOT1L 
(Feng et al. 2002). Hoxa5 and Hoxa9 loci were analyzed because they were shown to be 
required for leukemogenesis of various MLL-fusion proteins (Okada et al. 2005; Okada et al. 
2006; Faber et al. 2009). Hoxa10 was also included because its over-expression has been 
reported to induce transplantable AML in mice (Thorsteinsdottir et al. 1997). ChIP analysis 
verified that all three loci, in addition to Meis1, are preferentially enriched for H3K79me2/3 
in MLL-AF9 transformed cells when compared to control HPCs (Figure 3-6C,D). These data 
suggest that DOT1L-mediated H3K79 methylation contributes directly to Hoxa and Meis1 
gene activation in MLL-AF9 induced leukemogenesis.  
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Discussion 
Leukemia caused by MLL-AF9 fusions represents ~1/3 of all infant acute leukemias and 
~1/3 of adult AML (Krivtsov and Armstrong 2007). Recent studies demonstrating the 
interaction between MLL-AF9 and several functional partners such as Menin (Yokoyama et 
al. 2005; Chen et al. 2006; Caslini et al. 2007), wild-type MLL (Thiel et al. 2010), and the 
PAF complex (Milne et al. 2010; Muntean et al. 2010) have shed some light on the 
underlying mechanisms of MLL-AF9 leukemogenesis. DOT1L has been previously shown to 
directly interact with the C-terminus of AF9 (Zhang et al. 2006) and has been identified in 
AF9-associated protein complexes (Zeisig et al. 2005; Bitoun et al. 2007; Mueller et al. 
2009). In addition, H2B ubiquitination mediated by the PAF complex is required for both 
DOT1L methyltransferase activity (Krogan et al. 2003; Wood et al. 2003) and for MLL-AF9 
leukemic transformation (Milne et al. 2010; Muntean et al. 2010). These data suggest a 
possible link between DOT1L and MLL-AF9-mediated leukemogenesis. 
 
In this study, we demonstrate that DOT1L is required for the initiation of leukemic 
transformation by MLL-AF9 both in vitro by methylcellulose colony formation assays and in 
vivo by bone marrow transplantation assays (Figure 3-1). Additionally, we demonstrate that 
DOT1L is required for maintaining the transformed state of MLL-AF9 leukemic cells in vitro 
and in vivo as loss of DOT1L abrogated colony formation in methylcellulose colony re-
plating as well as AML progression in mice (Figure 3-2). Further analysis revealed that 
DOT1L is required for maintaining LSC identity, self-renewal capacity, and proliferation of 
MLL-AF9 transformed, but not MLL-AFX transformed, cells (Figures 3-2 and 3-3). 
Moreover, gene expression analysis demonstrates that activation of a group of LSC-
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associated genes, including the Hoxa cluster, Meis1, and Pbx3, is compromised upon loss of 
DOT1L function (Figure 3-4). Finally, ChIP assay supports that DOT1L-mediated H3K79 
methylation directly contributes to activation of these genes.  
 
It is important to note that during completion of this study two papers were published 
confirming a requirement for DOT1L in MLL-AF9 transformation (Chang et al. 2010; 
Monroe et al. 2011). However, neither one evaluated the role of DOT1L in vivo, leaving 
open the question of pathobiological relevance of their studies. Through bone marrow 
transplantation, we demonstrate that DOT1L plays a critical role in the initiation and 
maintenance of MLL-AF9-mediated acute leukemia; thus, firmly establishing the function of 
DOT1L in leukemogenesis. In contrast to our data on MLL-AFX, Chang and colleagues 
(Chang et al. 2010) found that DOT1L is required for maintaining MLL-AFX transformation 
in vitro. One possible explanation is that the two studies used different mouse models. Upon 
Cre-recombination of the Dot1L conditional allele in our mouse, both exons 5 and 6 are 
excised. Given that exons 4 and 7 will still be transcribed and translated in-frame, a truncated 
DOT1L mutant missing 108 residues within the catalytic domain can still be generated. 
However, recombination of the conditional allele used in Chang et al. only removes exon 5, 
which results in a frame-shift and the expression of a truncated protein containing only the 
first 87 residues (Chang et al. 2010). Their deletion may have a more severe phenotype due 
to loss of other DOT1L functions aside from its methyltransferase activity. 
 
We and others have previously shown that mis-targeting of DOT1L and subsequent 
methylation on H3K79 plays an important role in the leukemic process involving MLL-
 92 
 
AF10, MLL-ENL, MLL-AF4 transformation in vitro (Okada et al. 2005; Mueller et al. 2007; 
Krivtsov et al. 2008). Consistently, DOT1L has been shown to associate with all three of the 
aforementioned MLL fusion partners through direct or indirect interactions (Erfurth et al. 
2004; Okada et al. 2005; Zeisig et al. 2005; Bitoun et al. 2007; Mueller et al. 2007; Mueller 
et al. 2009). Of noteworthy, two reports have failed to identify DOT1L in an AF4-associated 
complex (Lin et al. 2010; Yokoyama et al. 2010), putting into question the role of DOT1L in 
MLL-AF4 leukemia. However, direct interaction of AF4 with AF9 and AF9 with DOT1L is 
unquestionable; thus, DOT1L may be mis-targeted to genomic loci by MLL-AF4 indirectly 
through their mutual association with AF9. In support of this possibility, it has been 
demonstrated that disruption of the AF4-AF9 interaction by the synthetic peptide PFWT 
inhibits MLL-AF4 leukemic cell proliferation (Srinivasan et al. 2004), which is similar to the 
results we observe with MLL-AF9 in the absence of DOT1L.  
 
This study, together with previous ones, strongly suggests a common mechanism by which 
DOT1L contributes to leukemogenesis of MLL-fusion proteins. We believe that mis-
targeting of DOT1L to Hoxa and Meis1 genes, subsequent H3K79 methylation, and up-
regulation of these genes is a common mechanism underlying the involvement of DOT1L in 
leukemogenesis (Figure 3-7). Although a similar mechanism for MLL-AF10 and MLL-AF4 
has been previously proposed (Okada et al. 2005; Guenther et al. 2008; Krivtsov et al. 2008), 
all previous studies were performed using an in vitro system with DOT1L knockdown. Here 
we not only extended the those studies by demonstrating the involvement of DOT1L in 
MLL-AF9 mediated leukemogenesis, but also provided the first evidence demonstrating an 
essential role for DOT1L in leukemogenesis in vivo. Our study thus solidifies DOT1L’s role 
 93 
 
in leukemias involving MLL rearrangements and makes DOT1L a prime candidate for 
targeted therapeutic intervention. 
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Materials and Methods 
Mice and in vivo Tamoxifen Treatment. The DOT1L conditional mouse was previously 
described (Jones et al. 2008). The R26-Cre-ERT2 mice were generated by Tyler Jacks lab 
(Ventura et al. 2007) and were obtained from the NCI Mouse Models of Human Cancers 
Consortium (Strain 01XAB). DOT1L2lox/+ and DOT1L1lox/+ mice were intercrossed to 
generate DOT1L2lox/1lox;Cre-ERT2 and DOT1L+/+;Cre-ERT2 mice. Mice were kept on a 
129Sv/Jae and C57/B6 Ly5.2 background. Wild type C57/B6 Ly5.1 and Ly5.2 mice were 
purchased from Jackson Laboratory and were intercrossed to generate Ly5.1/Ly5.2 mixed 
background BMCs. For in vivo Cre-recombination, tamoxifen (Sigma) was administered via 
intraperitoneal injection every 2 days (100 µl of 100 mg/ml in corn oil) for a period of 3 
weeks. All animal protocols adhere to the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals and were approved by the UNC Institutional Animal Care 
and Use Committee. 
Retrovirus Production, Transduction, Methylcellulose Colony Re-plating Assay, and 
Cell Culture. The pMSCN-MLL-AF9 construct was a gift from Jay Hess . The pMSCN-
MLL-AFX construct was a gift from Michael Cleary . Retroviral production was performed 
as described previously (Okada et al. 2005). Briefly, pMSCN-MLL-AF9 and pMSCN-MLL-
AFX were co-transfected with pGag-pol and pVSVG into 293T cells using Superfect 
(Qiagen). At 48 hrs post-transfection, viral supernatant were collected for transduction of c-
Kit positive HPCs purified as follows: Mice 4-10 weeks old were injected intravenously with 
5-fluorouracil (150 mg/kg). Bone marrow was harvested from both femurs 5 days post-
injection and stained with c-Kit-APC (BD Biosciences). Positive stained HPCs were FACS 
sorted using a BD FACSAria II Flow Cytometer. Viral supernatants were used to transduce 
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the FACS sorted cells via spinoculation, and cells plated onto methylcellulose 24hrs post-
infection. For methylcellulose colony formation assays, 1x10^4 transduced cells were plated 
into 0.9% Methocult M3534 (StemCell Technologies) supplemented with 10 ng/ml GM-CSF 
and 1 mg/ml G418 (GIBCO) for selection. After 7 days of culture, G418-resistant colonies 
were collected and single-cell suspensions re-plated into M3534 with GM-CSF in the 
absence of G418. Re-plating was performed every 7-10 days. Liquid cultures of transformed 
HPCs and LSCs were maintained in mFTOC (20% FBS in RPMI1640, 1 mM MEM sodium 
pyruvate, 1% MEM non-essential amino acid, 10 mM HEPES at pH 7.3, 50 µm 2-
mercaptoethanol with 5 ng/ml mIL-3 (Peprotech). For in vitro recombination, 4-OHT 
(Sigma) was resuspended in ethanol and added to cell culture media at final concentration of 
250 µM. Media was changed daily during 7 day period of 4-OHT treatment. 
Bone Marrow Transplantation. Recipient C57/B6 Ly5.1 mice (6-12 weeks old) began a 
prophylactic regimen to prevent gastro-intestinal infections through oral administration of 
sulfamethoxazole/trimethoprim (SMZ, TW Medical) at a concentration of 6 mg/1.2 mg per 
mL water one week prior to bone marrow transplantation (BMT) procedures and continued 
for 4 weeks post-transplantation.  SMZ containing water was changed every other day.  On 
the day of transplantation recipient mice received two doses, 4.8 Gy each, of total body 
irradiation (TBI) 4 hours apart using a cesium radiation source. Four hours after the second 
irradiation dose, recipient mice were anaesthetized through intraperitoneal injection of 300 ul 
per 10 g body weight of avertin (0.0125 g/ml 2,2,2, tribromoethanol and 1.25% tert-amyl 
alcohol in PBS).  Once anaesthetized, 0.5x10^5 LCs plus 2.5x10^5 radio-protector 
Ly5.1/Ly5.2 cells resuspended in 100 µl PBS (1:5 ratio) were transplanted via retro-orbital 
injection. 
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Histology. Tissues were harvested from mice and fixed in 4% paraformaldehyde. Livers 
were paraffin embedded and tissue sections, 5 µm thick, were used for hematoxylin and 
eosin staining.  
FACS Analysis and Cell Sorting. Bone marrow cells were flushed from both femurs of 
mice using 25G needle and syringe. Red blood cells were lysed using ammonium chloride 
(StemCell Technologies). Cells were resuspended in PBS + 2% FBS at a concentration of 
10^6 cells per 100 µl. Cells were stained for 30min at 40C, washed three times with PBS, and 
resuspended in PBS + 2% FBS. Antibodies used for FACS analysis and sorting are: Rat anti-
mouse c-Kit-APC, Ly5.1-PE-Cy7, and Ly5.2-PerCP-Cy5.5 plus corresponding Rat IgG2a 
Isotype controls (EBiosciences). All analysis and sorting was performed using BD FACSAria 
II Flow Cytometer. 
PI Staining for DNA content. Cells grown in liquid culture were washed twice with ice cold 
PBS and resuspended in 500 µl of PBS. While vortexing gently, 4.5 ml of ice cold 70% 
ethanol was slowly added and then stored at 40C overnight. On the following day, fixed cells 
were pelleted by centrifugation at 40C for 5 minutes at 1500rpm. Cell pellet was washed with 
PBS, centrifuged, and resuspended in 250 µl of PBS. PI staining mix (RNase A 100 µg/ml, 
propidium iodide 40 µg/ml, and 0.1% Triton X-100 in PBS) was prepared fresh, and 750 µl 
added to cells. Cells were incubated for 15 minutes at 370C and then analyzed by FACS 
using a Beckman Coulter CyAn Flow Cytometer. Data was analyzed using ModFit LT 
software. 
RT-qPCR and ChIP. For gene expression analysis, total RNA was isolated from cells using 
RNeasy Kit (Qiagen) and reverse transcribed using Improm II (Promega). SYBR GreenER 
qPCR SuperMix (Invitrogen) was used for qPCR.  qPCR was performed using Applied 
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Biosystems 7300 Real-Time PCR System. Relative expression was normalized to Gapdh. 
Primer sequences are listed in Table S3-1. ChIP experiments were carried out as previously 
described (Okada et al. 2005) with the following modifications. DNA was fragmented into 
300-500 bp in length by sonication. Immunoprecipitation was performed using anti-
H3K79me2/3 (Abcam) and anti-Rabbit IgG (Santa Cruz; sc-2027) and DynaBeads 
(Invitrogen).  ChIP’ed samples were washed twice with low salt (140mM NaCl) RIPA 
buffer, once with high salt (500 mM NaCl) RIPA buffer, and twice with TE buffer.  DNA 
was purified using Chelex-100. Quantitative real-time PCR of ChIP’ed DNA was analyzed 
using SYBR GreenER qPCR SuperMix (Invitrogen) and Applied Biosystems 7300 Real-
Time PCR System. Primer sequences are listed in Table S3-2. 
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Figure 3-1. DOT1L is required for MLL-AF9-induced leukemic transformation in vitro. 
(A) Diagram of the procedure used for in vitro analysis. (B) Bone marrow cells were stained 
with rat IgG2a-APC isotype control to identify c-Kit negative population. Bone marrow cells 
were stained with rat anti-mouse c-Kit-APC. c-Kit+ cells were sorted using a BD FACSAria 
II instrument. (C)RT-qPCR analysis of DOT1L expression level, normalized to Gapdh, after 
7 days of TAM treatment (250 nM final concentration) demonstrates efficient recombination. 
Mouse genotype is indicated. (D) Serial methylcellulose colony re-plating assay shows that 
MLL-AF9 fails to transform HPCs in the absence of DOT1L. An equal number of cells 
transduced with empty vector MSCN or MLL-AF9 were plated at each round and colony 
forming units (CFUs) counted after 7-10 days. Experiment was performed three times and 
presented as average number of CFUs with standard deviation (SD).  
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Figure 3-2. DOT1L is required for MLL-AF9-mediated leukemogenesis in vivo. (A) 
Diagram of the bone marrow transplantation procedure to examine the effect of DOT1L 
depletion on the establishment of AML by MLL-AF9 LCs in vivo. TAM treatment began at 3 
weeks post-transplantation. (B-G) In vivo deletion of DOT1L prevents MLL-AF9 mediated 
acute leukemia development. (B) Kaplan-Meier plot showing survival of transplanted mice 
treated and untreated with TAM. Median survival of wt/wt MLL-AF9 transplanted mice 
without TAM = 7 weeks (n=17) and wt/wt MLL-AF9 transplanted mice treated with TAM = 
7 weeks (n=14). All 2lox/1lox MLL-AF9 transplanted mice treated with TAM (n=18) survive 
at least 24 weeks post-transplantation. (C) Image of spleens harvested from transplanted 
mice at 6 weeks post-transplantation show splenomegaly in wt/wt MLL-AF9 transplanted 
mice. (D) H&E staining of liver tissue sections at 6 weeks post-transplantation show 
leukemic infiltration in wt/wt MLL-AF9 transplanted mice. (E) Donor leukemic cells 
depleted of DOT1L are absent in recipient bone marrow. Representative images showing 
FACS analysis of bone marrow cells isolated from transplanted mice. Donor MLL-AF9 LCs 
are Ly5.2+ (blue) while recipient/protector cells are Ly5.1+/Ly5.2+ (red). (F) Percentage of 
MLL-AF9 LCs present in recipient bone marrow at 6 and 9 weeks post-transplantation as 
determined by FACS analysis (n=3 per group). (G) No leukemic cells are detected by FACS 
analysis of peripheral blood obtained from 2lox/1lox MLL-AF9+TAM mice at 24 weeks 
post-transplantation. Representative image from one of the 6 mice analyzed. 
  
 102 
 
    
 
           
    
  
 103 
 
Figure 3-3. MLL-AF9 leukemic cells require DOT1L to maintain transformation in 
vitro. (A) Diagram of the procedure analyzing role of DOT1L for LC maintenance in vitro. 
(B) Genotyping to verify efficient Cre-mediated recombination of DOT1L2lox conditional 
allele. (C) RT-qPCR analysis of DOT1L expression level in 2lox/1lox MLL-AF9 LCs, 
normalized to Gapdh, after 7 days of TAM treatment (250 nM final concentration) 
demonstrates efficient recombination. (D) DOT1L is required for maintaining MLL-AF9 
leukemic transformation but not for MLL-AFX. Methylcellulose colony formation assay 
after TAM treatment of LCs. Equal number of cells were plated and average numbers of 
CFUs from 3 independent experiments are shown. Error bars represent SD.  
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Figure 3-4. DOT1L is required for MLL-AF9-induced acute leukemia progression in 
vivo. (A) Diagram of bone marrow transplantation procedure to examine the requirement of 
DOT1L in MLL-AF9 AML progression. TAM treatment began at 6 weeks post-
transplantation after leukemia development. (B-E) In vivo deletion of DOT1L prevents MLL-
AF9 acute myeloid leukemia progression. (B) Reduced spleen size in TAM-treated 2lox/1lox 
MLL-AF9 recipient mice. Representative images of spleens harvested from transplanted 
mice at 9 weeks post-transplantation. (C) TAM-induced DOT1L deletion prevents leukemic 
infiltration of the liver. H&E staining of liver tissue sections at 9 weeks post-transplantation. 
(D) Upon DOT1L depletion, the percentage of leukemic cells in bone marrow diminishes 
over time. FACS analysis of bone marrow cells isolated from transplanted mice. Donor 
MLL-AF9 LCs are Ly5.2+ (blue) while recipient/protector cells are Ly5.1+/Ly5.2+ (red). 
Percentage of donor Ly5.2 cells in the total bone marrow cell population at 9 weeks and 12 
weeks post-transplantation are indicated. At 12 weeks post-transplantation, cells were also 
stained with the stem cell/progenitor marker c-Kit. Leukemic donor Ly5.2 population is 
gated and percentage of c-Kit+ cells indicated. Shown are representative images from three 
independent experiments. (E) Loss of in vivo clonogenic leukemic stem cells after DOT1L 
depletion. Methylcellulose colony formation assay of LC donor cells sorted from mice at 12 
weeks post-transplantation. Average CFUs are shown for 3 different mice. Error bars 
represent SD. 
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Figure 3-5. Loss of DOT1L inhibits cell proliferation due to a G0/G1 cell cycle arrest. 
(A) In vitro TAM-induced DOT1L deletion inhibits MLL-AF9 LC proliferation in liquid 
culture but not MLL-AFX. Total cell numbers were counted every 2 days. Shown is the 
average of three independent experiments with error bars. (B) In vitro TAM-induced DOT1L 
deletion causes cell cycle arrest at G0/G1 phase for MLL-AF9 transformed cells. Cell cycle 
analysis was performed by propidium iodide staining. Experiment was repeated twice. Data 
was analyzed using ModFit software. (C) Gene expression analysis by RT-qPCR shows up-
regulation of CDK inhibitors after DOTL depletion, normalized to Gapdh. 
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Figure 3-6. DOT1L directly regulates expression of Hoxa and Meis1 genes in MLL-AF9 
leukemic cells. (A) RT-qPCR analysis shows up-regulation of Hoxa cluster and their co-
factors Meis1 and Pbx3, normalized to Gapdh, in MLL-AF9 LCs, which become down-
regulated upon DOT1L deletion. (B) RT-qPCR analysis shows down-regulation of myeloid 
differentiation markers, normalized to Gapdh, in MLL-AF9 LCs, which become up-regulated 
upon DOT1L deletion. (C) ChIP analysis demonstrates that H3K79me2/3 is enriched in 
Hoxa loci in MLL-AF9 LCs compared with that in the control HPCs. IgG was used for 
control ChIP and amplicon positions are indicated. TSS indicates transcription start site. (D) 
ChIP analysis demonstrates that H3K79me2/3 is enriched in the Meis1 gene in MLL-AF9 
LCs compared with that in the control HPCs. IgG was used for control ChIP and amplicon 
positions are indicated. TSS indicates transcription start site. 
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Figure 3-7. Model for mis-targeting of DOT1L by MLL-fusion proteins to up-regulate 
Hoxa gene expression. 
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Figure S3-1. In vivo tamoxifen-induced recombination efficiency. DOT1L2lox/1lox;Cre-
ERT2 mice were administered TAM via intraperitoneal injection every 2 days for 3 weeks. 
Bone marrow cells were purified to evaluate recombination efficiency by RT-qPCR. DOT1L 
expression was normalized to Gapdh. 
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Table S3-1. Primers used for RT-qPCR gene expression analysis. 
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Table S3-2. Primers used for ChIP-qPCR analysis. 
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PERSPECTIVES AND FUTURE DIRECTIONS  
 120 
 
DOT1L and the mammalian cell cycle 
The studies herein provide a small glimpse of the many functions of mammalian DOT1L. 
Without a doubt DOT1L is a critical enzyme for both normal biological and oncogenic 
processes. However, a great deal of information remains to be elucidated. For instance, 
exactly what part does DOT1L play in regulating cell cycle progression and the DNA 
damage response in mammalian cells? In yeast, Dot1 is a vital component of DNA damage 
repair pathways, but does this role translate into mammals?  
 
Thus far, several observations suggest mechanisms exist in mammalian cells involving 
DOT1L-mediated H3K79 methylation in checkpoint response and DNA replication. DOT1L 
knockout (KO) mouse embryonic stem (ES) cells exhibit a G2 arrest (Jones, Su et al. 2008) 
and aneuploidy, while KO erythroid progenitor cells undergo G1 arrest (Feng, Yang et al. 
2010). On the other hand, loss of DOT1L in cardiomyocytes and C2C12 myoblasts did not 
impair cell proliferation (Nguyen, Xiao et al. 2011). Of noteworthy, H3K79me2 patterns are 
also different between yeast and human. In HeLa cells, H3K79me2 is high in G1, decreases 
in S, reaches lowest point in G2, and increases again in M phase (Feng, Wang et al. 2002). 
However, in yeast, H3K79me2 is low in G1 and S, begins to increase in late S, and is 
maintained in G2 and M phases (Schulze, Jackson et al. 2009). It is apparent that mammalian 
DOT1L plays distinct cell type specific roles in regulating cell cycle progression. 
Additionally, these data suggest that not all functions of Dot1 are evolutionarily conserved 
from yeast to humans. Further studies are required to determine which DNA repair 
mechanisms involving DOT1L are conserved and to dissect the role of every H3K79 
methylation state during each phase of the mammalian cell cycle.  
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Maintaining telomere length in DOT1L-deficient cells 
A second area of divergence between yeast Dot1 and mammalian DOT1L is their role in 
telomere silencing. In yeast, Dot1 and its associated H3K79 methylation mark block SIR 
protein binding. In the absence of Dot1, SIR protein spreading occurs, diluting their ability to 
effectively maintain telomere silencing and, subsequently, reducing telomere lengths (Singer, 
Kahana et al. 1998; Ng, Feng et al. 2002; Ng, Ciccone et al. 2003). Surprisingly, ES cells 
derived from DOT1L KO embryos have longer, heterogeneous telomeres compared to wild 
type and heterozygote cells (Jones, Su et al. 2008). The aberrant telomere elongation 
observed in KO cells was attributed to activation of the alternative lengthening of telomere 
(ALT) pathway (Jones, Su et al. 2008). The ALT pathway utilizes homologous 
recombination for maintaining telomeres and can be activated in a number of human somatic 
cells and immortalized cells in response to reduced telomerase activity and to by-pass the 
end-replication problem (Bryan, Englezou et al. 1995; Bryan, Englezou et al. 1997; Henson, 
Neumann et al. 2002).  
 
Yeast cells that lack telomerase for maintaining telomere length die within 50-100 cell 
divisions. However, a small fraction of these cells can survive through two different 
mechanisms. Type I survivors use amplification of subtelomeric regions to maintain short 
telomeres (Lundblad and Blackburn 1993). Alternatively, type II survivors use the ALT 
pathway, acquiring a heterogeneous pool of long telomeres (Teng and Zakian 1999). In 
addition, Teng and Zakian demonstrate that type I survivors often convert to the ALT 
pathway to maintain telomere length (Teng and Zakian 1999). If the ALT pathway exists in 
yeast, it is unclear why it is not activated to by-pass the effects of Dot1 deletion for 
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regulating telomere length as is observed in DOT1L KO mouse ES cells. The inconsistency 
in telomere regulation upon loss of yeast Dot1 and mouse DOT1L signifies the need for more 
in-depth analysis of mammalian DOT1L. 
 
DOT1L as a therapeutic target to treat MLL-related leukemias 
Chromosomal rearrangement of the Philadelphia chromosome in chronic myeloid leukemia 
(CML) was first identified in 1973, and the protein product, Bcr-Abl, was demonstrated to be 
the causative agent in 1990. The oncogenic function of Bcr-Abl is mediated by the 
constitutively active tyrosine kinase domain of Abl. In 1996, Imatinib (also known as 
Gleevec), a 2-phenyaminopyrimidine derivative, was discovered as a selective inhibitor of 
tyrosine kinase activity of Bcr-Abl, platelet-derived growth factor (PDGF-R), and c-Kit. 
Surprisingly, the drug had no effect on normal cells and is well tolerated with minor side 
effects. Therefore, in December of 2002, Imatinib was FDA approved for targeted therapy to 
treat human CML (Deininger and Druker 2003).  
 
The first 11q23 rearrangement in acute leukemia was identified in 1985. In 1992, several labs 
mapped the chromosomal breakpoint region at 11q23 to the MLL gene, a homolog of the 
Drosophila gene trithorax (Gu, Nakamura et al. 1992; McCabe, Burnett et al. 1992; 
Tkachuk, Kohler et al. 1992). Although it has been almost two decades since the discovery of 
MLL rearrangements as a cause of acute leukemias, no effective target-based therapy has 
been developed. The lack of targeted therapeutics to treat MLL-related leukemias may be due 
to the large heterogeneity of MLL rearrangements (over 50 different translocation partners). 
Mounting evidence supports a universal mechanism by which oncogenic MLL-fusion 
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proteins mistarget DOT1L to Hoxa and Meis1 genes for H3K79 hypermethylation, up-
regulation, and leukemogenesis. In this dissertation, I demonstrated for the first time that 
DOT1L activity is essential for acute myeloid leukemia development and progression in the 
mouse. These data suggest that targeting DOT1L may be an effective therapeutic to treat the 
majority of MLL-related leukemias.  
 
Due to the unique structure of DOT1L’s catalytic domain compared to all other histone 
lysine methyltransferases (Min, Feng et al. 2003), the ability to generate specific inhibitors of 
DOT1L HMTase activity is feasible. Unfortunately, at least in the mouse, DOT1L is an 
essential enzyme required for development (Jones, Su et al. 2008), ES cell maintenance 
(Jones, Su et al. 2008; Barry, Krueger et al. 2009), cardiac function (Nguyen, Xiao et al. 
2011), and hematopoiesis (Feng, Yang et al. 2010). Leukemia patients treated with DOT1L 
inhibitors may develop adverse side effects, including anemia and heart disease. Therefore, 
any drug designed to inhibit DOT1L enzymatic activity for the treatment of MLL-related 
leukemias must be carefully and thoroughly characterized both in vitro and in vivo long term. 
It is my hope that one day, a drug will be developed that specifically targets DOT1L in 
leukemic cells, leaving normal cells unscathed, reminiscent of Imatinib.  
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